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Heart	 failure	 is	 a	 serious,	 life-threatening	 condition.	 Despite	 significant	 advances	 in	 both	
pharmacological	 and	 device	 therapies,	 significant	 morbidity	 and	 mortality	 remain	 a	 reality.	 The	
ability	 to	 monitor,	 identify	 and	 intervene	 on	 those	 most	 at	 risk	 to	 prevent	 further	 clinical	
deterioration	continues	to	be	a	goal	of	healthcare	providers	around	the	world.		
	
Despite	 their	 established	 role	 in	 the	 diagnosis	 and	 prognosis	 of	 heart	 failure,	 use	 of	 the	 B-type	
natriuretic	 peptides,	 BNP	 and	 NTproBNP	 to	 monitor	 patients	 with	 chronic	 heart	 failure	 has	 been	
disappointing.	 Such	 results	have,	 in	part,	been	attributed	 to	 the	high	biological	 variability	of	 these	
peptides.	Over	the	past	decade	numerous	novel	biomarkers	associated	with	heart	failure	have	been	
identified.	 Several	 of	 these	 have	 shown	 significant	 prognostic	 potential.	 Evidence	 supporting	 their	
use	for	monitoring	remains	lacking.	
	
The	 aim	 of	 this	 thesis	 is	 to	 assess	 the	 potential	 of	 four	 novel	 biomarkers	 of	 heart	 failure	 for	
monitoring	pharmacologically	optimised,	stable	chronic	heart	failure	patients,	both	in	terms	of	their	
biological	 variability	and	how	 this	 translates	 into	 the	ability	 for	 changes	 in	 serial	measurements	 to	
predict	cardiovascular	admission.	Mid-regional	pro-adrenomedullin,	apelin,	soluble	ST2	and	galectin-
3	 were	 chosen	 due	 to	 previous	 promising	 results	 with	 respect	 to	 prognosis	 and	 their	 range	 of	
reflection	of	several	different	underlying	pathological	processes.		
	
The	 hypothesis	 was	 that	 that	 one	 or	 more	 of	 these	 biomarkers	 would	 have	 lower	 biological	
variability	than	NTproBNP	and	that	this	would	translate	into	serial	changes	being	better	at	predicting	







Results	 demonstrated	 that	 all	 four	 novel	 biomarkers	 show	 lower	 biological	 variability	 than	 that	 of	
NTproBNP.	 This,	 however,	 did	 not	 consistently	 translate	 into	 improved	 ability	 for	 serial	
measurements	 to	 predict	 cardiovascular	 admission.	 The	 use	 of	 biomarkers	 for	 monitoring	 may	
depend	more	on	the	pathophysiological	process	being	measured	and	the	association	of	any	marker	
with	that	process.		Biomarkers	of	hypertrophy	and	fibrosis,	galectin-3	and	sST2,	appear	to	show	the	
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ACE-I	 	 	 	 	 	 Angiotensin	converting	enzyme	inhibitor	
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AHF	 	 	 	 	 	 Acute	heart	failure	
Ang	II	 	 	 	 	 	 Angiotensin	II	
ANP	 	 	 	 	 	 Atrial	natriuretic	peptide	
APJ	 	 	 	 	 	 Apelin	receptor	
ARB	 	 	 	 	 	 Angiotensin	II	receptor	blocker	
AUC	 	 	 	 	 	 Area	under	curve	
b-blocker	 	 	 	 	 Beta-blocker	
BNP	 	 	 	 	 	 Brain	natriuretic	peptide	 	
cAMP	 	 	 	 	 	 Cyclic	adenosine	monophosphate	
CHF	 	 	 	 	 	 Chronic	heart	failure	
cGMP	 	 	 	 	 	 Cyclic	guanosine	monophosphate	
CGRP	 	 	 	 	 	 Calcitonin	gene	related	peptide	
CNP	 	 	 	 	 	 C-type	natriuretic	peptide	
CRP	 	 	 	 	 	 C-reactive	protein	
CRT	 	 	 	 	 	 Cardiac	resynchronisation	therapy	
CV	 	 	 	 	 	 Cardiovascular	
CVa	 	 	 	 	 	 Analytical	coefficient	of	variation	
CVg	 	 	 	 	 	 Inter-individual	coefficient	of	variation	
CVi	 	 	 	 	 	 Intra-individual	coefficient	of	variation	
CVt	 	 	 	 	 	 Total	coefficient	of	variation	
ECG	 	 	 	 	 	 Electrocardiogram	





EIA	 	 	 	 	 	 Enzyme	immunoassay	
ELISA	 	 	 	 	 	 Enzyme	linked	immunosorbent	assay	
eNOS	 	 	 	 	 	 Endothelial	nitric	oxide	synthase	
ESC	 	 	 	 	 	 European	Society	of	Cardiology	 	
Hb	 	 	 	 	 	 Haemoglobin	 	 	
HF	 	 	 	 	 	 Heart	failure	
IL-33	 	 	 	 	 	 Interleukin	33	
IQR	 	 	 	 	 	 Interquartile	range	
LBBB	 	 	 	 	 	 Left	bundle	branch	block	
LVEF	 	 	 	 	 	 Left	ventricular	ejection	fraction	
LVSD	 	 	 	 	 	 Left	ventricular	systolic	dysfunction	
MD	 	 	 	 	 	 Doctorate	of	medicine	
MRA	 	 	 	 	 	 Mineralocorticoid	receptor	antagonist	
mRNA	 	 	 	 	 	 Messenger	ribonucleic	acid	
MRproADM	 	 	 	 	 Mid-regional	pro-adrenomedullin	
MRproANP	 	 	 	 	 Mid-regional	pro-atrial	natriuretic	peptide	
Na	 	 	 	 	 	 Sodium	
NICE	 	 	 	 	 	 National	Institute	for	Health	and	Care	Excellence	
NO	 	 	 	 	 	 Nitric	oxide	
NPPB	 	 	 	 	 	 Natriuretic	peptide	precursor	B	 	 	
NPR-A	 	 	 	 	 	 Natriuretic	peptide	receptor	A	
NPV	 	 	 	 	 	 Negative	predictive	value	
NRES	 	 	 	 	 	 National	Research	Ethics	Service	
NTproANP	 	 	 	 	 N-terminal	pro-atrial	natriuretic	peptide	
NTproBNP	 	 	 	 	 N-terminal	pro-brain	natriuretic	peptide	





OLT	 	 	 	 	 	 Orthotopic	liver	transplantation	
preproADM	 	 	 	 	 Pre-pro-adrenomedullin	
RAAS	 	 	 	 	 	 Renin-angiotensin-aldosterone	system	
RCT	 	 	 	 	 	 Randomised	controlled	trial	
RCV	 	 	 	 	 	 Reference	change	value	
RIA	 	 	 	 	 	 Radioimmunoassay	
RNA	 	 	 	 	 	 Ribonucleic	acid	
ROC	 	 	 	 	 	 Receiver	operator	curve	
RRR	 	 	 	 	 	 Relative	risk	reduction	
SD	 	 	 	 	 	 Standard	deviation	
ST2	 	 	 	 	 	 Suppression	of	tumorigenicity	2	
sST2	 	 	 	 	 	 Soluble	suppression	of	tumorigenicity	2	
ST2L	 	 	 	 	 	 Transmembrane	suppression	of	tumorigenicity		
STEMI	 	 	 	 	 	 ST	elevation	myocardial	infarction	
SV	 	 	 	 	 	 Stroke	volume	
TNFα	 	 	 	 	 	 Tumour	necrosis	factor	alpha	





















of	 an	 impaired	 ability	 of	 the	 heart	 to	 function	 as	 a	 pump	 to	 support	 physiological	 circulation.	
Conceptually,	 it	 is	 a	 syndrome	 rather	 than	 a	 definitive	 diagnosis,	 typified	 by	 symptoms	 of	
breathlessness	and	fatigue	combined	with	signs	of	fluid	overload.		
	
The	 clinical	 syndrome	 of	 HF	 may	 result	 from	 disorders	 of	 the	 pericardium,	 myocardium,	
endocardium,	great	vessels,	or	conducting	system	but	the	majority	of	patients	have	symptoms	due	

































From	 a	 health-economic	 perspective,	 it	 is	 one	 of	 the	 most	 common	 reasons	 for	 emergency	
admission,	 readmission	 and	bed	occupancy.	 Recent	 estimates	 suggest	HF	 accounts	 for	 one	million	





hypertension,	 is	 accountable	 for	 approximately	 two-thirds	 of	 cases	 of	 LVSD.	 In	 a	 study	 of	 left	
ventricular	 function	 in	North	Glasgow(9),	95%	vs	71%	of	symptomatic	and	asymptomatic	 individuals	
with	definite	LVSD	had	evidence	of	CAD	(p = 0.04).	Those	individuals	with	symptoms	were	also	more	
likely	to	have	a	history	of	myocardial	infarction	(50%	vs	14%;	p = 0.01)	and	concurrent	angina	(62%	vs	







Despite	 such	 findings,	 there	 are	many	 other	 identifiable	 causes	 of	HF	 (table	 1),	 the	 prevalence	 of	
which	will	 depend	on	 the	 geographical	 location	and	demographics	of	 the	 cohort	 examined.	 In	 the	




Web Table 3 Aetiology of heart failure
There is no agreed or satisfactory classiﬁcation for the causes of HF, with much overlap between potential categories
Myocardial disease 
1. Coronary artery disease
2. Hypertensiona
3. Cardiomyopathyb
  a. Familial
   i. Hypertrophic
   ii. Dilated
   iii. Arrhythmogenic right ventricular cardiomyopathy
   iv. Restrictive
   v. Left ventricular non-compaction
  b. Acquiredc
   i. Myocarditis (inﬂammatory cardiomyopathy)
    Infective
     • Bacterial
     • Spirochaetal
     • Fungal
     • Protozoal
     • Parasitic
     • Rickettsial
     • Viral
    Immune-mediated
     • Tetanus toxoid, vaccines, serum sickness
     • Drugs
     • Lymphocytic/giant cell myocarditis
     • Sarcoidosis
     • Autoimmune
     • Eosinophilic (Churg–Strauss)
    Toxic
     • Drugs (e.g. chemotherapy, cocaine)  
     • Alcohol
     • Heavy metals (copper, iron, lead)
   ii. Endocrine/nutritional
     • Phaeochromocytoma
     • Vitamin deﬁciency (e.g. thiamine)
     • Selenium deﬁciency
     • Hypophosphataemia
     • Hypocalcaemia
   iii. Pregnancy
   iv. Inﬁltration
     • Amyloidosis










     • Endomyocardial diseases with hypereosinophilia [hypereosinophilic syndromes (HES)]
     • Endomyocardial disease without hypereosinophilia [e.g. endomyocardial ﬁbrosis (EMF)]







  Sinus node dysfunction
Conduction disorders
     • Atrioventricular block
High output states
     • Anaemia
     • Sepsis
     • Thyrotoxicosis
     • Paget’s disease
     • Arteriovenous ﬁstula
Volume overload
     • Renal failure
     • Iatrogenic (e.g. post-operative ﬂuid infusion)
AV = atrioventricular; HF = heart failure.
aBoth peripheral arterial and myocardial factors contribute to the development of heart failure.
















approximately	 60–100ml(23,	 24).	 SV	 is	 affected	 by	 three	 main	 factors:	 preload,	 the	 amount	 of	
myocardial	fibre	stretch	at	the	end	of	diastole;	afterload,	the	resistance	that	must	be	overcome	for	





understanding	 is	 derived	 from	 studies	 of	 myocardial	 infarction(25-28)	 and	 therefore,	 it	 is	 the	
mechanism	 of	 LVSD	 that	 remains	 the	 best	 documented.	 In	 such	 cases,	 systolic	 dysfunction	 is	 the	
result	 of	 reduced	 myocardial	 contractility	 or	 significantly	 increased	 impedance	 to	 left	 ventricular	
ejection	 leading	 to	 a	 reduction	 in	 the	 ability	 of	 the	 myocardial	 sarcomeres	 to	 shorten.	 As	
factors: preload, which is the amount of myocardial fiber
stretch at the end of diastole; afterload, which is the resistance
that must be overcome in order for the ventricle to eject blood;
and contractility, which is the inotropic state of the heart
independent of the preload or the afterload.
5.2. Left ventricular dysfunction
Left ventricular (LV) dysfunction can be divided into two
categories: systolic dysfunction (impaired ventricular con-
traction and ejection) and diastolic dysfunction (impaired
relaxation and ventricular filling). Although there are many
etiologies of HF, some tend to more adversely affect systolic
or diastolic function, though 70% of patients with HF have
systolic dysfunction compared to 30% with diastolic
dysfunction [14]. In addition, most patients with systolic
dysfunction also have a component of diastolic dysfunction.
Whether or not a patient with HF has systolic or diastolic
dysfunction depends on the ejection fraction (EF), which is
defined as the amount of blood pumped from the ventricle in
one heartbeat. If the EF is b40%, it is s stolic dysfunction,
and if it is N40%, it is diastolic dysfunction.
LV systolic dysfunction is defined as an LVEF less than
40% (Fig. 2). The leading cause of LV systolic dysfunction
is loss of functional myocardium due to ischemic disease and
infarction. Uncontrolled hypertension leading to excessive
pressure overload is another leading factor. Volume overload
due to valvular incompetence, and impaired contractility
from cardiotoxins and cardiotoxic drugs are also contribu-
tors. The consequence of LV dysfunction is decreased CO
which in turn leads to global hypoperfusion. In addition, LV
dysfunction causes an increase in the amount of blood in the
ventricle and therefore an increase in both end-systolic and
end-diastolic volumes. This in turn leads to an increase in LV
end-diastolic pressure (LVEDP) which causes elevations in
left atrial pressures which in turn lead to increases in the
pressur of the capillaries in the lungs. This elevated pressure
in the lungs forces fluid out of the pulmonary capillaries and
leads to pulmonary congestion and the major clinical
symptom of dyspnea.
It is important, however, to understand that the
symptoms of systolic and diastolic HF are the same, and
whether a patient has systolic or diastolic dysfunction
depends on the EF. Patient symptoms must correlate to
their physical signs in order for them to be diagnostic of
HF. These signs and symptoms of LV dysfunction are all
the result of increased left atrial pressure and pulmonary
congestion (Table 2).
5.3. Right ventricular dysfunction
The most common cause of right ventricular (RV)
failure is LV failure. As the RV fails, there is a similar
increase in the amount of blood in the ventricle, which in
turn leads to elevated right atrial pressure and increased
pressure in the vena caval system which impairs venous
drainage from the body. This leads to increased pressure in
the liver, the gastrointestinal tract, and the lower
extremities and to the clinical signs and symptoms of
abdominal pain, hepatomegaly, and peripheral edema.
(Table 3). Other causes of RV failure include arrhythmo-
genic RV cardiomyopathy/dysplasia.
Fig. 1. Factors affecting CO.
Fig. 2. Left ventricular dysfunction.
Table 2
Signs and symptoms of LV failure
LV dysfunction
Symptoms Signs
Dyspnea on exertion Basilar rales





Signs and symptoms of RV failure
RV dysfunction
Symptoms Signs
Abdominal pain Peripheral edema
Anorexia Jugular venous distension
Nausea Abdominal–jugular reflex
Bloating Hepatomegaly





physiological	circulation	succumbs	to	the	resultant	reduction	 in	cardiac	output	and	 increase	 in	wall	
stress,	activation	of	complex	compensatory	mechanisms	from	the	subcellular	to	the	organ-to-organ	
level	 ensues.	 Many	 of	 these	 mechanisms	 rely	 on	 the	 activation	 of	 neurohormonal	 systems	 to	
maintain	arterial	pressure,	myocyte	contractility	and	ultimately	the	perfusion	of	vital	organs.	These	
mechanisms	 predominantly,	 but	 not	 exclusively,	 involve	 the	 renin-angiotensin-aldosterone	 system	








ABC of heart failure
Pathophysiology
G Jackson, C R Gibbs, M K Davies, G Y H Lip
Heart failure is a multisystem disorder which is characterised by
abnormalities of cardiac, skeletal muscle, and renal function;
stimulation of the sympathetic nervous system; and a complex
pattern of neurohormonal changes.
Myocardial systolic dysfunction
The primary abnormality in non-valvar heart failure is an
impairment in left ventricular function, leading to a fall in
cardiac output. The fall in cardiac output leads to activation of
several neurohormonal compensatory mechanisms aimed at
improving the mechanical environment of the heart. Activation
of the sympathetic system, for example, tries to maintain cardiac
output with an increase in heart rate, increased myocardial
contractility, and peripheral vasoconstriction (increased
catecholamines). Activation of the renin-angiotensin-
aldosterone system (RAAS) also results in vasoconstriction
(angiotensin) and an increase in blood volume, with retention
of salt and water (aldosterone). Concentrations of vasopressin
and natriuretic peptides increase. Furthermore, there may be
progressive cardiac dilatation or alterations in cardiac structure
(remodelling), or both.
Neurohormonal activation
Chronic heart failure is associated with neurohormonal
activation and alterations in autonomic control. Although these
compensatory neurohormonal mechanisms provide valuable
support for the heart in normal physiological circumstances,
they also have a fundamental role in the development and
subsequent progression of chronic heart failure.
Renin-angiotensin-aldosterone system
Stimulation of the renin-angiotensin-aldosterone system leads
to increased concentrations of renin, plasma angiotensin II, and
aldosterone. Angiotensin II is a potent vasoconstrictor of the
renal (efferent arterioles) and systemic circulation, where it
stimulates release of noradrenaline from sympathetic nerve
terminals, inhibits vagal tone, and promotes the release of
aldosterone. This leads to the retention of sodium and water
and the increased excretion of potassium. In addition,
angiotensin II has important effects on cardiac myocytes and
may contribute to the endothelial dysfunction that is observed
in chronic heart failure.
Sympathetic nervous system
The sympathetic nervous system is activated in heart failure, via
low and high pressure baroreceptors, as an early compensatory
mechanism which provides inotropic support and maintains
cardiac output. Chronic sympathetic activation, however, has
deleterious effects, causing a further deterioration in cardiac
function.
The earliest increase in sympathetic activity is detected in
the heart, and this seems to precede the increase in sympathetic
outflow to skeletal muscle and the kidneys that is present in
advanced heart failure. Sustained sympathetic stimulation
activates the renin-angiotensin-aldosterone system and other
neurohormones, leading to increased venous and arterial tone
Developments in our understanding of
the pathophysiology of heart failure have
been essential for recent therapeutic
advances in this area
Poor ventricular function/myocardial damage
(eg post myocardial infarction, dilated cardiomyopathy)
Decreased stroke volume and cardiac output
• Vasoconstriction: increased sympathetic tone, angiotensin II, endothelins,
   impaired nitric oxide release
• Sodium and fluid retention: increased vasopressin and aldosterone
Neurohormonal response
Further stress on ventricular wall and dilatation (remodelling)
leading to worsening of ventricular function
Activation of sympathetic system Renin angiotensin aldosterone system
Heart failure
Further heart failure
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(and greater preload and afterload respectively), increased
plasma noradrenaline concentrations, progressive retention of
salt and water, and oedema. Excessive sympathetic activity is
also associated with cardiac myocyte apoptosis, hypertrophy,
and focal myocardial necrosis.
In the long term, the ability of the myocardium to respond
to chronic high concentrations of catecholamines is attenuated
by a down regulation in ‚ receptors, although this may be
associated with baroreceptor dysfunction and a further increase
in sympathetic activity. Indeed, abnormalities of baroreceptor
function are well documented in chronic heart failure, along
with reduced parasympathetic tone, leading to abnormal
autonomic modulation of the sinus node. Moreover, a reduction
in heart rate variability has consistently been observed in
chronic heart failure, as a result of predominantly sympathetic
and reduced vagal modulation of the sinus node, which may be
a prognostic marker in patients with chronic heart failure.
Natriuretic peptides
There are three natriuretic peptides, of similar structure, and
these exert a wide range of effects on the heart, kidneys, and
central nervous system.
Atrial natriuretic peptide (ANP) is released from the atria in
response to stretch, leading to natriuresis and vasodilatation. In
humans, brain natriuretic peptide (BNP) is also released from
the heart, predominantly from the ventricles, and its actions are
similar to those of atrial natriuretic peptide. C-type natriuretic
peptide is limited to the vascular endothelium and central
nervous system and has only limited effects on natriuresis and
vasodilatation.
The atrial and brain natriuretic peptides increase in
response to volume expansion and pressure overload of the
heart and act as physiological antagonists to the effects of
angiotensin II on vascular tone, aldosterone secretion, and
renal-tubule sodium reabsorption. As the natriuretic peptides
are important mediators, with increased circulating
concentrations in patients with heart failure, interest has
developed in both the diagnostic and prognostic potential of
these peptides. Substantial interest has been expressed about
the therapeutic potential of natriuretic peptides, particularly
with the development of agents that inhibit the enzyme that
metabolises atrial natriuretic peptide (neutral endopeptidase),
and non-peptide agonists for the A and B receptors.
Antidiuretic hormone (vasopressin)
Antidiuretic hormone concentrations are also increased in
severe chronic heart failure. High concentrations of the
hormone are particularly common in patients receiving diuretic
treatment, and this may contribute to the development of
hyponatraemia.
Endothelins
Endothelin is secreted by vascular endothelial cells and is a
potent vasoconstrictor peptide that has pronounced
vasoconstrictor effects on the renal vasculature, promoting the
retention of sodium. Importantly, the plasma concentration of
endothelin-1 is of prognostic significance and is increased in
proportion to the symptomatic and haemodynamic severity of
heart failure. Endothelin concentration is also correlated with
indices of severity such as the pulmonary artery capillary wedge
pressure, need for admission to hospital, and death.
In view of the vasoconstrictor properties of endothelin,
interest has developed in endothelin receptor antagonists as
cardioprotective agents which inhibit endothelin mediated
vascular and myocardial remodelling.
Other hormonal mechanisms in chronic heart failure
x The arachidonic acid cascade leads to increased concentrations of
prostaglandins (prostaglandin E2 and prostaglandin I2), which
protect the glomerular microcirculation during renal
vasoconstriction and maintain glomerular filtration by dilating
afferent glomerular arterioles
x The kallikrein kinin system forms bradykinin, resulting in both
natriuresis and vasodilatation, and stimulates the production of
prostaglandins
x Circulating concentrations of the cytokine tumour necrosis factor
(·TNF) are increased in cachectic patients with chronic heart
failure. ·TNF has also been implicated in the development of
endothelial abnormalities in patients with chronic heart failure
Myocardial damage




Fluid retention Increased wall stress
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proliferation	 and	myocyte	 hypertrophy.	 Pressure	 overload	 tends	 towards	 the	 laying	 down	 of	 new	
sarcomeres	that	 increase	myocyte	width	 (concentric	hypertrophy),	whereas	volume	overload	 leads	
to	the	replication	of	sarcomeres	in	series	and	elongation	of	myocytes	(eccentric	hypertrophy)(27,	30).	If	
left	 unchecked,	 these	 processes	 result	 in	 structural	 changes,	 leading	 to	 a	 reduction	 in	 fibre	
shortening,	 a	 decrease	 in	 left	 ventricular	 ejection	 fraction	 (LVEF)	 and	 ultimately	 left	 ventricular	
spherical	dilatation	-	a	phenomenon	known	as	remodelling.	Furthermore,	ventricular	dilatation	may	
subsequently	lead	to	stretching	of	the	mitral	valve	ring,	resulting	in	valvular	incompetence.	Although	
this	phenomenon	results	 in	ventricular	offloading	via	the	atria,	 the	 increased	workload	required	to	
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Heart failure is a multisystem disorder which is characterised by
abnormalities of cardiac, skeletal muscle, and renal function;
stimulation of the sympathetic nervous system; and a com lex
pattern of neurohormonal changes.
Myocardial systolic dysfunction
The primary abnormality in non-valvar heart failure is an
impairment in left ventricular function, leading to a fall in
cardiac output. The fall in cardiac output leads to activation of
several neurohormonal compensatory mechanisms aimed at
improving the mechanical environment of the heart. Activation
of the sympathetic system, for example, tries to maintain cardiac
output with an increase in heart rate, increased myocardial
contractility, and peripheral vasoconstriction (increased
catecholamines). Activation of the renin-angiotensin-
aldosterone system (RAAS) also results in vasoconstriction
(angiotensin) and an increase in blood volume, with retention
of salt and water (aldosterone). Concentrations of vasopressin
and natriuretic peptides increase. Furthermore, there may be
progressive cardiac dilatation or alterations in cardiac structure
(remodelling), or both.
Neurohormonal activation
Chronic heart failure is associated with neurohormonal
activation and alterations in autonomic control. Although these
compensatory neurohormonal mechanisms provide valuable
support for the heart in normal physiological circumstances,
they also have a fundamental role in the development and
subsequent progression of chronic heart failure.
Renin-angiotensin-aldosterone system
Stimulation of the renin-angiotensin-aldosterone system leads
to increased concentrations of renin, plasma angiotensin II, and
aldosterone. Angiotensin II is a potent vasoconstrictor of the
renal (efferent arterioles) and systemic circulation, where it
stimulates release of noradrenaline from sympathetic nerve
terminals, inhibits vagal tone, and promotes the release of
aldosterone. This leads to the retention of sodium and water
and the increased excretion of potassium. In addition,
angiotensin II has important effects on cardiac myocytes and
may contribute to the endothelial dysfunction that is observed
in chronic heart failure.
Sympathetic nervous system
The sympathetic nervous system is activated in heart failure, via
low and high pressure baroreceptors, as an early compensatory
mechanism which provides inotropic support and maintains
cardiac output. Chronic sympathetic activation, however, has
deleterious effects, causing a further deterioration in cardiac
function.
The earliest increase in sympathetic activity is detected in
the heart, and this seems to precede the increase in sympathetic
outflow to skeletal muscle and the kidneys that is present in
advanced heart failure. Sustained sympathetic stimulation
activates the renin-angiotensin-aldosterone system and other
neurohormones, leading to increased venous and arterial tone
Developments in our understanding of
the pathophysiology of heart failure have
been essential for recent therapeutic
advances in this area
Poor ventricular function/myocardial damage
(eg post myocardial infarction, dilated cardiomyopathy)
Decreased stroke volume and cardiac output
• Vasoconstriction: increased sympathetic tone, angiotensin II, endothelins,
   impaired nitric oxide release
• Sodium and fluid retention: increased vasopressin and aldosterone
Neurohormonal response
Further stress on ventricular wall and dilatation (remodelling)
leading to worsening of ventricular function
Activation of sympathetic system Renin angiotensin aldosterone system
Heart failure
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vessels,	 kidneys,	 and	 muscles.	 Coupled	 with	 electrolyte	 imbalances,	 the	 release	 of	 inflammatory	
cytokines,	oxygen	 free	 radicals	 and	endothelins,	 the	 result	 is	 a	pathophysiological	 viscous	 cycle,	 in	
which	further	electrical	and	mechanical	dysfunction	of	the	heart	ensues.		
	
Exceptions	 to	 these	 processes	 are	 the	 release	 of	 the	 natriuretic	 peptides	 and	 endogenous	






always	posed	a	 challenge	 to	 the	diagnostic	abilities	of	 the	physician,	with	 further	advice	 regarding	
those	who	should	then	be	referred	for	specialist	opinion	also	being	previously	lacking.	Indeed,	some	
early	studies	suggested	that	less	than	half	of	those	patients	with	a	primary	care	setting	diagnosis	of	
HF	went	on	 to	have	 their	diagnosis	 confirmed	with	 cardiac	 imaging	and	evaluation	 in	 a	 secondary	
centre(31).	 Furthermore,	 given	 the	 low	diagnostic	 yield	of	 echocardiography	 in	patients	with	only	 a	





accurately	 established	 via	 the	 use	 of	 cardiac	 imaging,	 most	 commonly	 echocardiography(32-36).	

















routine laboratory tests provide valuable prognostic information
(see Section 6).
3.6.7 Algorithm for the diagnosis of heart failure
An algorithm for the diagnosis of HF or LV dysfunction is shown in
Figure 1.
In patients presenting to hospital as an emergency with sus-
pected HF and acute onset of symptoms, early echocardiog-
raphy is recommended (and immediate echocardiography in
shocked or severely haemodynamically compromised patients).
If a natriuretic peptide is measured, a high exclusion cut-off
point should be used.39–50 In patients presenting
non-emergently in primary care, or to a hospital outpatient
Acute onset Non-acute onset
ECG 
Chest x-ray
Echocardiography BNP/NT-pro BNP* BNP/NT-pro BNP Echocardiography

























If heart failure confirmed, 
determine aetiologyd and 
start appropriate treatment
*In the acute setting, MR-proANP may also be used (cut-off point 120 pmol/L, i.e. <120 pmol/L = heart failure unlikely). 
BNP = B-type natriuretic peptide; ECG = electrocardiogram; HF = heart failure; MR-proANP = mid-regional pro atrial natriuretic peptide; 
NT-proBNP = N-terminal pro B-type natriuretic peptide.
a Exclusion cut-off points for natriuretic peptides are chosen to minimize the false-negative rate while reducing unnecessary referrals for echocardiography.
b Other causes of elevated natriuretic peptide levels in the acute setting are an acute coronary syndrome, atrial or ventricular arrhythmias, pulmonary embolism, and severe 
chronic obstructive pulmonary disease with elevated right heart pressures, renal failure, and sepsis. Other causes of an elevated natriuretic level in the non-acute setting are: 
old age (>75 years), atrial arrhythmias, left ventricular hypertrophy, chronic obstructive pulmonary disease, and chronic kidney disease.
c Treatment may reduce natriuretic peptide concentration, and natriuretic peptide concentrations may not be markedly elevated in patients with HF-PEF.
dSee Section 3.5 and Web Table 3.
Figure 1 Diagnostic flowchart for patients with suspected heart failure—showing alternative ‘echocardiography first’ (blue) or ‘natriuretic















Two	 key	 randomised	 controlled	 trials,	 Cooperative	 North	 Scandinavian	 Enalapril	 Survival	 Study	
(CONSENSUS)(3)	and	Studies	of	Left	Ventricular	Dysfunction	(SOLVD)(4),		advocated	the	use	of	ACE-I		in	
the	 full	 spectrum	 of	 patients	 with	 symptomatic	 HF	 secondary	 to	 LVSD.	 Results	 of	 these	 trials	
demonstrated	 a	 relative	 risk	 reduction	 (RRR)	 in	 mortality	 of	 27%	 and	 16%	 and	 an	 absolute	 risk	
reduction	 of	 14.6%	 and	 4.5%	 respectively.	 With	 an	 additional	 26%	 relative	 risk	 reduction	 in	 HF	
hospitalisation	 observed	 in	 SOLVD	 and	 further	 corroboration	 of	 results	 by	 a	 wealth	 of	 additional	
studies	 and	 subsequent	 meta-analyses(38-42),	 the	 2012	 European	 Society	 of	 Cardiology	 (ESC)	




Despite	 initial	 fears	 regarding	 the	 use	 of	 beta-blockers	 in	 patients	 with	 LVSD(43-45),	 several	 pivotal	
trials	 were	 successfully	 able	 to	 demonstrate,	 not	 only	 their	 safety	 when	 initiated	 in	 the	 chronic	
phase,	but	substantial	benefits	in	both	mortality	and	reverse	remodelling.	Three	such	trials,	Cardiac	
Insufficiency	Bisoprolol	 Study	 II	 (CIBIS	 II)(5),	 Carvedilol	 Prospective	Randomized	Cumulative	 Survival	
(COPERNICUS)(46),	 and	Metoprolol	CR/XL	Randomised	 Intervention	Trial	 in	Congestive	Heart	Failure	
(MERIT-HF)(47)	 showed	 that	beta-blocker	 treatment	 resulted	 in	a	RRR	 in	mortality	of	approximately	
34%	and	 in	HF	hospitalisation	of	28–36%	within	1	 year	of	 starting	 treatment.	 These	benefits	were	
additional	 to	 those	gained	with	 conventional	 treatment,	 including	an	ACE	 inhibitor	 and	have	been	










mineralocorticoid	 receptor	 antagonists	 (MRAs)	 in	 patients	 with	 EF≤35%	 and	 New	 York	 Heart	
Association	 (NYHA)	 functional	 class	 II-IV.	 Both	 trials	 demonstrated	 RRR	 in	 mortality	 and	 HF	
hospitalisations	of	30-37%	within	approximately	2	years	of	 starting	 treatment,	over	and	above	 the	
benefits	obtained	from	conventional	therapy,	including	both	ACE-I	and	beta-blockers.	As	a	result	of	
the	EMPHASIS-HF	trial,	the	recommendations	for	the	use	of	MRAs	in	LVSD	has	increased	from	IB	to	








The	 CHARM-Alternative(55)	 trial	 was	 a	 placebo-controlled	 randomised	 controlled	 trial	 (RCT)	 with	
Candesartan	in	2028	patients,	intolerant	of	an	ACE-I	with	an	LVEF	≤40%.	Treatment	with	Candesartan	
















Only	one	 large	 trial	 has	examined	 the	use	of	digoxin	 in	patients	with	 symptomatic	 LVSD	 (EF≤45%)	
who	 were	 in	 sinus	 rhythm(56).	 In	 this,	 treatment	 with	 digoxin	 was	 associated	 with	 a	 RRR	 in	 HF	
hospitalisation	 of	 28%	 within	 three	 years	 of	 starting	 treatment.	 There	 was,	 however,	 no	
demonstrable	 mortality	 benefit.	 The	 2012	 ESC	 guidance	 therefore	 advises	 that	 digoxin	 may	 be	
considered	to	reduce	the	risk	of	HF	hospitalization	in	patients	in	sinus	rhythm	with	an	EF≤45%	who	
are	 unable	 to	 tolerate	 a	 beta-blocker	 or	 with	 persisting	 symptoms	 (NYHA	 class	 II–IV)	 despite	
treatment	with	a	beta-blocker,	ACE-I	or	ARB	and	an	MRA(22).	The	use	of	digoxin	in	the	setting	of	atrial	




Several	 studies	 have	 demonstrated	 mortality	 benefits	 related	 to	 heart	 rate	 control	 in	 chronic	 HF	
patients(3-5,	 57).	 Ivabradine	 is	a	novel	pharmacological	agent	 that	 inhibits	 the	 If	channel	of	 the	sinus	






from	 the	addition	of	 Ivabradine,	with	a	RRR	 in	 the	primary	 composite	outcome	of	CV	death	or	HF	
hospitalization	of	18%.	Of	note,	 the	 reduction	 in	CV	death	 (or	all-cause	death)	 at	 this	 target	heart	











evidence-based	 dose	 of	 beta-blocker	 (or	maximum	 tolerated	 dose),	 ACE-I	 or	 ARB	 and	 an	MRA(22).’	
The	 Medicines	 and	 Healthcare	 products	 Regulatory	 Authority	 (MHRA)	 and	 National	 Institute	 for	
Health	and	Care	Excellence	(NICE),	however,	took	a	different	stance,	and	concluded	that	the	benefits	
of	 the	 drug	were	 only	 significantly	 demonstrable	 in	 patients	with	 heart	 rates	 of	 ≥75bpm.	 For	 this	
reason,	 in	 the	UK,	 Ivabradine	 is	 recommended	only	 for	patients	 in	sinus	 rhythm,	with	an	EF	≤35%,	





ethnic	 differences	 in	 response	 to	 HF	 therapy.	 Specifically,	 in	 V-HeFT	 I(60),	 the	 combination	 of	
isosorbide	dinitrate	(ISDN)	and	hydralazine	significantly	reduced	mortality	in	Black	patients,	but	not	
Caucasians.	Furthermore,	 in	V-HeFT	 II(61),	 the	ACE-I	enalapril	provided	significant	benefit	 compared	







Despite	 such	 findings,	 both	 the	 V-HeFT	 and	 A-HeFT	 trials	 were	 relatively	 small,	 making	 definitive	















the	 novel	 angiotensin-neprilysin	 inhibitor	 sacubitril-valsartan	 was	 compared	 with	 enalapril	 in	
patients	with	HF	and	reduced	ejection	fraction	(LVEF≤35%).	The	primary	endpoint	was	a	composite	
of	 death	 from	 cardiovascular	 causes	 or	 hospitalisation	 for	 HF.	 The	 trial	 was	 stopped	 early	 after	 a	
median	 follow-up	 of	 27	 months	 when	 the	 boundary	 for	 an	 overwhelming	 benefit	 in	 favour	 of	
sacubitril-valsartan	was	crossed.		
	
Neprilysin	 is	 a	 neural	 endopeptidase	 which	 degrades	 several	 endogenous	 vasoactive	 peptides,	
including	 the	 natriuretic	 peptides,	which	 are	 discussed	 in	more	 detail	 in	 section	 1.3	 of	 this	 thesis.	
Inhibition	 of	 neprilysin	 increases	 the	 levels	 of	 these	 substances,	 counteracting	 the	 activation	 of	
pathophysiological	neurohormonal	processes	responsible	for	vasoconstriction,	sodium	retention	and	




Results	 of	 the	 PARADIGM-HF	 trial	 demonstrated	 an	 approximate	 20%	 reduction,	 not	 only	 in	 the	
composite	primary	endpoint,	but	in	cardiovascular	mortality,	all-cause	mortality	and	hospitalisation	





standard	therapy	as	opposed	to	placebo.	Given	the	magnitude	of	the	results,	 it	 is	highly	 likely	that	
sacubitril-valsartan	will	change	the	face	of	chronic	HF	therapy,	with	the	potential	to	replace	ACE-I	as	
first	 line	 treatment.	As	a	 result	of	PARADIGM-HF,	sacubitril-valsartan	received	European	marketing	
authorisation	 in	November	2015,	with	the	first	patients	receiving	treatment	soon	after.	 It’s	use	for	












in	 addition	 to	 conventional	 treatment	 including	 an	 ACE-I	 or	 ARB,	 beta-blocker	 and	 MRA.	 ICD	
treatment	 led	to	a	RRR	 in	death	of	23%	over	a	median	 follow-up	of	45.5	months.	This	benefit	was	






Several	 large	 randomised	 controlled	 trials	 have	 demonstrated	 significant	 mortality	 and	 morbidity	





(NYHA	 class	 II-IV),	 reduced	 ejection	 fraction	 (EF≤35%),	 and	 are	 in	 sinus	 rhythm	 with	 evidence	 of	
dysynchrony	on	ECG(69-72).	 Two	key	placebo	controlled	 randomised	controlled	 trials,	Comparison	of	
Medical	 Therapy,	 Pacing	 and	 Defibrillation	 in	 Heart	 Failure	 (COMPANION)	 and	 Cardiac	
Resynchronisation	in	Heart	Failure	(CARE-HF),	demonstrated	RRR	in	death	and	HF	hospitalisations	of	
24-52%	 in	 patients	 with	 NYHA	 class	 III-IV	 symptoms	 and	 QRS	 duration	 of	 ≥120ms(69,	 70).	 Similar	
benefits	 were	 demonstrated	 in	 those	 with	 NHYA	 Class	 (II-III)	 symptoms	 in	 the	





Despite	 such	 findings,	 CRT	 is	 not	 a	 benign	 therapy	 and	 can	 be	 associated	 with	 significant	
complications	and	 the	 identification	of	patients	most	 likely	 to	benefit	has	been	 the	 focus	of	much	
work.	 Particular	 interest	 has	 been	 paid	 to	 the	 ECG	 parameters	 of	 QRS	morphology	 and	 duration.	
Whilst	 there	 is	 clear	 evidence	 of	 benefit	 in	 those	 with	 LBBB	 and	 QRS	 duration	 of	 ≥150ms,	 the	
evidence	for	those	with	non-LBBB	or	QRS	duration	of	<150ms	is	less	robust(69-73).		
	




group	 compared	 with	 the	 control	 group	 (11.1%	 vs.	 6.4%	 respectively,	 p=0.02).	 Much	 of	 this	 was	













Patients	 with	 HF	 who	 cannot	 be	 stabilised	 with	 medical	 or	 device	 therapy	 may	 benefit	 from	




The	 use	 of	 intra-aortic	 balloon	 pumps	 in	 cardiogenic	 shock	 are	 not	 recommended	 and	 should	 be	
reserved	 for	 those	 patients	 who	 require	 circulatory	 support	 before	 surgical	 correction	 of	 specific	
acute	mechanical	 problems	 (e.g.	 interventricular	 septal	 rupture	 and	 acute	mitral	 regurgitation)	 or	





Percutaneous	 ventricular	 assist	 devices	 (pVADs)	 are	 being	 increasingly	 used	 in	 patients	 with	
cardiogenic	shock.	They	offer	a	means	of	instituting	rapid	and	adequate	cardiac	support	in	patients	
with	cardiogenic	shock	unresponsive	to	inotropes/vasopressors	and	IABP.	Currently	available	pVADs	
include	 the	 TandemHeart,	 Impella	 and	 extracorporeal	 membrane	 circulation	 (ECMO).	 pVADs	
compensate	for	the	loss	of	myocardial	pump	function,	normalizing	cardiac	output	and	thus	allowing	










There	 is	 considerable	 debate	 on	 the	 appropriate	 use	 of	 these	 devices	 given	 the	 difficulty	 of	
conducting	 randomised	 trials	 in	 patients	 with	 cardiogenic	 shock,	 lack	 of	 clear	 guidelines	 on	
indications,	 device	 selection,	 and	 cost-effective	 care	of	 patients	 implanted	with	 these	devices.	 	 To	
date,	most	 clinical	 trials	 have	demonstrated	 that,	whilst	 these	devices	 do	 indeed	provide	 superior	
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(2) Refractory arrhythmias: recurrent ventricular fibrilla-
tion/ventricular tachycardia storm/high-risk ventricu-
lar tachycardia ablations
(3) ‘Bridge-to-decision’ in young postcardiac arrest
patients with uncertain neurological status
(4) ‘High-risk PCI’ in patients with left main disease,
multivessel percutaneous coronary intervention
(PCI), and severe left ventricular dysfunction.
Mechanical circulatory support for
cardiogenic shock
Although no single percutaneous assist device is ‘ideal’
for all patients, the inherent traits of such a device should
include the following:
(1) Ease of implantation via percutaneous approach.
(2) Ability to rapidly provide adequate flow (even in the
face of increased systemic vascular resistance) to
maintain systemic perfusion and reverse end-organ
dysfunction.
(3) Provide adequate unloading of the ventricle.
(4) Easy and uncomplicated operation.
(5) Low complication rates (limb ischemia/stroke/
hemolysis).
Theuseof thesedevices shouldbe tailored for eachpatient
based on the degree of hemodynamic support needed to
reverse/prevent progression of cardiogenic shock.
The currently available percutaneous assist devices for
cardiogenic shock are compared in Table 1.
Current status of percutaneous assist devices for
cardiogenic shock
pVADs compensate for the loss of myocardial pump
function, normalizing cardiac output and thus allowing
physiologic perfusion of vital organs as compared with
IABP, which solely decreases afterload and increases
coronary blood flow. The improved hemodynamic
support afforded by the use of percutaneous assist
devices helps attenuate the severe inflammatory
reaction associated with refractory cardiogenic shock
and improves end-organ perfusion [7]. Animal studies
have demonstrated reduced infarct size associated with
the use of percutaneous LVADs [8,9]. Additionally, the
use of percutaneous LVADs reduces ventricular strain
and negative remodeling and may lead to better long-
term outcomes. Although most of the patients implanted
with a pVAD eventually get revascularized or implanted
with an LVAD, this may be the basis of recovery seen in
some of the patients who are able to regain their ven-
tricular function while on mechanical circulatory support.
Specific percutaneous assist devices
Currently available devices include IABP, TandemHeart
pVAD, Impella Recover system, and percutaneous extra-
corporeal membrane oxygenation (ECMO).
Intraaortic balloon pulsation
IABP has stood the test of time and is currently the most
frequently used assist device for cardiogenic shock. It
works on the principle of diastolic inflation and systolic
deflation resulting in decreased afterload and increased
coronary perfusion pressure, and can augment cardiac
550 Ischemic heart disease
Table 1 Comparison of intraaortic balloon pump and currently available percutaneous ventricular assist devices for cardiogenic
shock
IABP TandemHeart pVAD Impella 2.5 Recover system ECMO
Pump mechanism Pneumatic Centrifugal Axial flow Centrifugal flow
Insertion Retrograde 7-9F balloon
catheter into descending
aorta via femoral artery
21F inflow cannula into





12F catheter (13F sheath)
placed retrograde across
the aortic valve via
femoral artery
18–31F inflow cannula
into the right atrium




Difficulty of insertion þ þþþþ þþþ þþ
Degree of support þ þþþ þþ þþþþ
(* CO by 0.5 l/min) (* CO by 3.5–4 l/min) (* CO by 2.5 l/min) (* CO to >4.5 l/min)
Cardiac power outputa þ þþþ þþ þþþþ
Time for implantation 10min 25–65min 11–25min 10–15min
Limb ischemia þ þþþ þþ þþþ
Hemolysis 0 þþ þþþþ þþþ





(may be placed with
antegrade sideport for
limb perfusion), RV failure
LV thrombus, ventricular septal
defect, severe aortic stenosis,






AI, aortic insufficiency; CO, cardiac output; E MO, extracorporeal membrane oxygenation; IABP, intraaortic balloon pump; LV, left ventricular; pVAD,
percutaneous ventricular assist device; RV, right ventricular.
a Cardiac power output, measured in watts, is defined as the mean arterial pressure (MAP) multiplied by CO divided by 451. Takes into account the
need for adequate MAPs as well as CO for adequate end-organ perfusion and has prognostic utility in predicting mortality in cardiogenic shock















on	 the	 transplant	waiting	 list(90).	Accordingly,	MCS	devices,	particularly	 continuous-flow	LVADs,	are	
increasingly	 being	 viewed	 as	 a	 potential	 alternative	 to	 heart	 transplantation.	 Initially	 LVADs	 were	





In	 the	UK,	however,	 the	NHS	only	supports	 the	use	of	LVADs	as	a	bridge	to	transplant.	 It	does	not	
fund	 ‘destination	 therapy’.	 However,	 whilst	 the	 number	 of	 transplants	 remains	 lower	 than	 the	
number	 of	 patients	 currently	 on	 the	 transplant	 list,	 the	 number	 of	 patients	 on	 long	 term	 LVAD	


















treatment	 for	 selected	 patients	 with	 end-stage	 HF.	 Apart	 from	 the	 shortage	 of	 donor	 hearts,	 the	
main	 challenges	 in	 transplantation	 are	 ensuring	 appropriate	 patient	 selection	 and	 the	 subsequent	
consequences	and	complications	of	 long	 term	 immunosuppressive	 therapy	 (i.e.	antibody-mediated	
rejection,	infection,	hypertension,	renal	failure,	malignancy	and	coronary	artery	vasculopathy).		
	






Despite	major	 advances	 in	 treatment,	 HF	 still	 has	 a	 prognosis	 worse	 than	 that	 of	 the	majority	 of	
breast	and	prostate	cancers	and	is	associated	with	poor	quality	of	life	in	many	patients(98,	99).	Survival	
rates	 for	 patients	 who	 receive	 sub-optimal	 care	 are	 poor,	 with	 40%	 of	 newly	 diagnosed	 patients	
dying	 within	 a	 year(100),	 and	 total	 annual	 mortality	 ranging	 from	 10-40%,	 depending	 on	 disease	
severity.		
In	 order	 to	 improve	 clinical	 outcomes	 (better	 quality	 of	 life,	 reduced	mortality	 and	morbidity	 and	












Despite	 significant	advances	 in	 the	 treatment	of	 chronic	HF	with	both	pharmacological	 and	device	
therapy,	 hospitalisation	 rates	 remain	 unacceptably	 high,	 with	 30-day	 readmission	 rates	 currently	
estimated	 at	 20-25%(104-106).	 Efforts	 to	 reduce	 this	 figure	 have	 focused	 on	 the	 use	 of	 improved	




With	 the	 increased	 use	 of	 device	 therapy,	 so	 came	 the	 opportunity	 to	 utilize	 the	 sophisticated	





artery	 pressure,	 left	 atrial	 pressure,	 as	well	 as	 a	 combination	 of	 parameters.	Whilst	 several	meta-
analyses	 examining	 the	 clinical	 benefit	 of	 these	 approaches	 have	 been	 encouraging(107-109),	
prospective	clinical	trials	have	produced	variable	results(110-116).	
	
There	 has,	 however,	 been	 some	 success	 using	 the	 CardioMEMsTM	 wireless	 pulmonary	 artery	







artery	 pressure	 monitoring	 in	 addition	 to	 standard	 care	 compared	 with	 standard	 care	 alone(117).	
Subsequent	data	confirmed	these	results	with	a	33%	reduction	in	HF	related	hospitalisations	over	an	
extended	18-month	 follow-up	period(118).	 In	 2014,	 the	CardioMEMSTM	 sensor	became	 the	 first	 FDA	
approved	 implantable	wireless	heart	monitoring	device	 for	 the	 remote	management	of	chronic	HF	
patients.		
	
More	 recently,	 the	 INfluence	 of	 home	monitoring	 on	mortality	 and	morbidity	 in	 HF	 patients	with	
IMpaired	lEft	ventricular	function	(IN-TIME)	trial	assessed	the	benefits	of	automatic	multi-parameter	
telemonitoring	for	patients	with	HF	treated	with	an	ICD	or	CRT-D(119).	The	primary	outcome	measure	
was	 a	 composite	 clinical	 score	 combining	 all-cause	 death,	 overnight	 hospital	 admission	 for	 HF,	
change	in	NYHA	class,	and	change	in	patient	global	self-assessment.	Results	demonstrated	that	the	
odds	 of	 a	 worsening	 composite	 score	 were	 37%	 higher	 in	 the	 control	 group	 compared	 to	 those	
managed	with	telemonitoring.	
	
















hospitalisations(122-126).	 Although	 recent	meta-analyses	 of	 RCTs	 suggests	 that	 structured	 telephone	





With	 the	 identification	of	 prognostic	 biomarkers	 for	HF,	 the	 potential	 for	 these	markers	 to	 detect	








Biomarkers	 are	 ‘cellular,	 biochemical	 or	 molecular	 alterations	 that	 are	 measurable	 in	 biological	
media	 such	 as	 human	 tissues,	 cells,	 or	 fluids.’(139)	 More	 recently,	 the	 National	 Institute	 of	 Health	
(NIH)	definition	of	a	biomarker	has	expanded	this	definition	to	 include	any	biological	characteristic	






Although	 many	 biological	 markers	 fulfil	 this	 definition	 and	 are	 utilised	 extensively	 in	 research	































goal	 of	 increasing	 the	 probability	 of	 a	 given	 diagnosis.	 If	 a	 biomarker	 is	 to	 be	 used	 to	 aid	 the	
diagnostic	conundrum,	it	should	be	sensitive	and	specific	and	have	a	high	predictive	value.	A	highly	
sensitive	 test	will	 be	positive	 in	nearly	 all	 patients	with	 the	disease,	 but	 it	may	also	be	positive	 in	
many	 patients	 without	 the	 disease.	 Therefore,	 to	 be	 of	 clinical	 value,	 a	 test	 with	 high	 sensitivity	
should	 also	 have	 high	 specificity;	 in	 other	 words,	 most	 patients	 without	 the	 disease	 should	 have	






Most	 biological	 markers,	 however,	 are	 not	 simply	 present	 or	 absent,	 but	 have	 wide	 ranges	 of	
concentrations	 that	 overlap	 those	 with	 disease	 and	 those	 without	 it.	 The	 likelihood	 of	 disease	
presence	 typically	 increases	 progressively	with	 increasing	 levels,	 so	 various	 cut-off	 points	must	 be	
evaluated	for	their	ability	to	detect	disease.	Cut-off	points	with	high	sensitivity,	producing	few	false	
negative	results,	are	used	when	the	consequences	of	missing	a	potential	case	are	severe,	whereas	





disease	 compared	 with	 a	 rare	 disease.	 It	 is	 therefore	 necessary	 to	 consider	 the	 likelihood	 of	 the	
































	 (LR+)	 		=	 True	positives	 												=		 			Sensitivity															




(LR-)	 		=	 False	negatives	 												=		 (1-Sensitivity)	
	 	 	 True	negatives	 	 	 			Specificity	
	
The	 further	 away	 a	 likelihood	 ratio	 (LR)	 is	 from	 1,	 the	 stronger	 the	 evidence	 for	 the	 presence	 or	


















The	 principles	 of	 a	 screening	 programme	 are	 to	 detect	 disease	 in	 a	 population	 at	 an	 early	 stage,	
enabling	earlier	intervention	and	management	in	the	hope	of	reducing	mortality	and	morbidity	from	
the	disease.	Although	screening	may	 lead	to	an	earlier	diagnosis,	not	all	screening	tests	have	been	

























Many	 patients	 newly	 diagnosed	 with	 disease	 pose	 questions	 regarding	 prognosis.	 Predicting	 the	
course	of	a	particular	disease	in	a	particular	individual	remains	challenging	due	to	the	contribution	of	
various	factors	including	patient	demographic,	co-morbidities	and	disease	specific	features.	The	use	





















With	 the	 ability	 to	 prognosticate,	 comes	 the	 potential	 to	monitor	 disease	 progression.	 The	 use	 of	
serial	sampling	to	detect	important	changes	prior	to	the	onset	of	symptoms	is	an	attractive	method	
for	 selecting	 patients	 for	 early	 intervention	 and	 prevention	 of	 costly	 hospital	 admissions.	 From	 a	







Although	 biomarkers	 have	 numerous	 advantages,	 variability	 is	 a	 major	 concern.	 Several	 factors	
within	the	environment,	the	individual	and	within	the	test	itself	contribute	to	variability	and	various	
measures	can	be	taken	in	order	to	reduce	the	impact	of	these	on	the	final	result	(table	4)(144).	While	
measurement	 error	 is	 always	 a	 concern	 with	 biomarkers,	 other	 important	 factors	 may	 explain	








attributed	 to	 the	 effects	 of	 factors	 such	 as	 concurrent	 disease	 states	 or	 other	 personal	
characteristics.	The	amount	of	body	 fat,	 for	example,	 can	 influence	 the	biological	measurement	of	
several	biomarkers.		
	








In	 the	study	of	biological	variation,	 several	different	 indices	can	be	calculated	 in	order	 to	estimate	
these	variances(145):		
• Total	Coefficient	of	Variation	(CVt)	-	composed	of	both	analytic	and	biologic	variation.		
• Analytical	 Coefficient	of	Variation	 (CVa)	 -	 the	 variation	 that	 exists	within	 the	measurement	
process.	This	is	normally	kept	to	a	small	fraction	of	the	intra	and	inter-individual	variances.	





• Index	 of	 Individuality	 –	 the	 ratio	 of	 intra-individual	 to	 inter-individual	 variation	 (CVi/CVg).	





Inherent	 to	 the	 use	 of	 any	 biomarker	 derived	 from	 body	 tissue	 in	 a	 clinical	 setting	 is	 the	
understanding	of	how	these	variables	affect	concentrations	both	in	the	healthy	and	disease	state.	A	
single	 measurement	 of	 an	 analyte	 represents	 a	 concentration	 that	 independently	 randomly	
fluctuates	 around	a	normal	 homeostatic	 set	 point.	 	However,	 knowledge	of	 the	 temporal	 changes	
following	 acute	 episodes	 of	 disease	 is	 a	 necessary	 prerequisite	 for	 the	 selection	 of	 the	 most	
appropriate	 test(s)	 to	aid	diagnosis	and	 is	 vital	 for	 the	correct	 interpretation	of	 results.	As	with	all	
clinical	 analytes,	 the	biomarkers	of	disease	change	with	 time	and	 stages	of	disease.	Consequently,	










where	 Z	 (the	 95%	 confidence	 interval	 Z	 score)	 is	 1.96.	 This	 level	 of	 RCV	 reflects	 the	 minimum	







pathways	activated	may	be	 leveraged	for	biological	monitoring.	Consequently,	 there	are	 increasing	














































Of	 the	 recognised	 potential	 biomarkers,	 the	 B-type	 natriuretic	 peptides	 are	 the	 most	 extensively	
studied	 and	 currently	 utilised.	Whilst	 the	 ability	 of	 the	 heart	 to	 induce	 natriuresis	 in	 response	 to	
atrial	stretch	was	first	recognised	in	the	1950’s(148),	 it	was	not	until	the	early	1980’s	that	the	first	of	
these,	atrial	natriuretic	peptide	(ANP),	was	formally	identified(149).	In	1988	it	was	further	discovered	
that	 brain	 natriuretic	 peptide	 (BNP),	 a	 peptide	 initially	 isolated	 from	 pig	 brain	 but	 primarily	
synthesised	by	 the	ventricular	myocardium(150),	produced	similar	natriuretic	and	diuretic	 responses	
as	ANP.	Using	models	of	experimental	HF	and	from	human	subjects,	it	was	demonstrated	that	both	




BNP	production	in	normal	healthy	 individuals	 is	minimal.	 In	response	to	myocyte	stretch,	however,	
the	BNP	gene,	natriuretic	peptide	precursor	B	(NPPB),	expressed	within	the	heart,	produces	an	initial	
134	amino	acid	pre-proBNP	precursor	peptide.	Removal	of	a	26-amino	acid	signal	peptide	results	in	
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Fig. 1. Cardiac natriuretic peptides ANP (28 aminoacids) and BNP (32 aminoacids) are homologous in structure, forming a ring with a disulfide
bridge. Identical aminoacids are marked black.
Fig. 2. Schematic drawing of proBNP showing enzymatic cleavage into biologically active BNP and NT-proBNP.
BNP hormone is separate from the n-terminal part of
the prohormone termed NT-proBNP (Fig. 2). It is
currently debated when and where the prohormone split
takes place since small amounts of intact proBNP may
be found in the circulation and split prohormone can be
found in cellular extracts. Data from in vitro experiments
indicate that the proteolytic enzyme furin is responsible





Subsequent	 binding	 of	 the	 active	 peptide	 to	 its	 receptor,	 natriuretic	 peptide	 receptor	 A	 (NPR-A)	
activates	the	production	of	the	second	messenger	cyclic	guanosine	monophosphate	(cGMP),	which	
mediates	 the	 effects	 of	 BNP.	 The	 net	 result	 is	 that	 of	 inhibition	 of	 sodium	 reabsorption	 in	 the	
proximal	convoluted	tubule	and	natriuresis,	increase	in	glomerular	filtration	and	diuresis,	relaxation	
of	 vascular	 smooth	 muscle	 and	 vasodilatation.	 Overall	 this	 leads	 to	 reduced	 blood	 pressure,	






Regulation	 of	 BNP	 production	 occurs	 at	 the	 level	 of	 gene	 expression,	 and	 can	 increase	 rapidly	 in	
response	 to	a	 trigger	 stimulus(157).	Although	 this	 is	primarily	myocyte	stretch,	other	 stimuli	 such	as	
tachycardia,	 left	ventricular	hypertrophy,	 ischaemia,	hypoxaemia,	 sepsis,	 thyroid	dysfunction,	 renal	
dysfunction,	 pulmonary	 embolism	and	 liver	 cirrhosis	 can	 also	 trigger	 gene	 expression	 and	 thereby	
























of	 BNP	 in	 the	 diagnosis	 of	 HF	 and	 led	 to	 the	widespread	 clinical	 use	 of	 BNP.	 In	 particular,	with	 a	
negative	predictive	value	(NPV)	of	87%	with	BNP	levels	less	than	100pg/ml	and	an	NPV	of	97%	with	





it	 is	unlikely	 that	neprilysin	 inhibition	will	have	commenced	 in	 those	without	a	 formal	diagnosis	of	










Given	 the	 relationship	 with	 left	 ventricular	 stretch	 and	 filling	 pressures,	 it	 is	 unsurprising	 that	
circulating	BNP	and	NTproBNP	levels	are	not	only	associated	with	diagnostic	accuracy,	but	also	with	
prognostic	accuracy	 in	patients	with	HF(173-177).	 In	 these	patients,	higher	concentrations	of	BNP	and	
NTproBNP	are	associated	with	increased	cardiovascular	and	all-cause	mortality,	independent	of	age,	












Given	 their	 correlation	 with	 prognosis,	 it	 is	 logical	 to	 assume	 that	 serial	 measurement	 of	 BNP	 or	
NTproBNP	 might	 prove	 useful	 in	 optimising	 pharmacotherapy	 for	 chronic	 HF	 and	 in	 so	 doing,	
improve	patient	outcomes.	Initial	small	studies	proved	inconclusive	in	this	respect.	Whilst	Troughton	







in	hospitalisations	or	mortality	with	 such	a	 strategy(180).	 In	order	 to	 fully	 elucidate	 the	potential	 of	
natriuretic	peptides	in	this	respect,	several	larger	randomised	clinical	trials	have	evaluated	whether	





Serial	 CARdiac	 Readmissions	 and	Death	 (BATTLESCARRED)	 trial	 to	 assess	 the	 benefit	 of	 natriuretic	
peptide	 guided	 therapy(183).	 Compared	 with	 usual	 care	 in	 the	 community,	 intensive	 management	
with	or	without	serial	natriuretic	peptide	monitoring	improved	mortality	at	one	year	in	patients	with	
chronic	 HF	 but	 at	 two	 and	 three	 years,	 there	 was	 no	 significant	 difference	 between	 treatments	
overall.	 Sub	 group	 analysis,	 however,	 did	 reveal	 that	mortality	 and	 hospital	 admission	 rates	were	
reduced	with	peptide-guided	 therapy	 compared	with	usual	 care	 in	patients	 younger	 than	 seventy-
five	years.	No	benefits	were	observed	in	patients	older	than	seventy-five	years.		
	
The	Trial	of	 Intensified	Versus	Standard	Medical	 Therapy	 in	Elderly	Patients	with	Congestive	Heart	
Failure	 (TIME-CHF)	was	subsequently	designed	to	evaluate	 the	use	of	NTproBNP	guided	therapy	 in	
younger	patients	(60	to	74	years)	compared	with	an	older	cohort	(75	years	or	greater)(182).	Mortality	
was	 significantly	 reduced	 in	 the	younger	age	group	but	no	such	benefit	was	observed	 in	 the	older	
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similar	 effects	 on	 pharmacotherapy	 but	 results	 pertaining	 to	 improvement	 in	mortality/morbidity	
have	been	less	convincing(133,	 135,	 181,	 184).	With	an	almost	equal	number	of	studies	showing	‘positive’	
and	‘neutral’	results,	and	in	an	overall	relatively	small	number	of	patients,	three	meta-analyses	have	








All-cause mortality (Figure 2). Natriuretic peptide-guided
therapy (using either BNP- or NT-proBNP-guided) led to
a significant reduction of all-cause mortality (OR: 0.738; 95%
CI: 0.596 to 0.913; comparison p= 0.005; heterogeneity p= 0.896)
without heterogeneity among studies. When separately analyzed,
NT-proBNP-guided therapy significantly reduced all-cause mor-
tality (OR: 0.717; 95% CI: 0.563 to 0.914; comparison p= 0.007;
heterogeneity p = 0.692), whereas BNP-guided therapy did not
(OR: 0.814; 95% CI: 0.518 to 1.279; comparison p= 0.371;
heterogeneity p = 0.823).
HF-related hospitalization (Figure 3). Natriuretic peptide-
guided therapy led to a significant reduction of HF-related
hospitalization (OR: 0.554; 95% CI: 0.399 to 0.769; comparison
p= 0.000; heterogeneity p = 0.019). When separately assessed,
NT-proBNP-guided therapy significantly reduced HF-related
hospitalization (OR: 0.531; 95% CI: 0.347 to 0.811; comparison
p= 0.003; heterogeneity p= 0.032), whereas BNP-guided therapy
did not (OR: 0.599; 95% CI: 0.303 to 1.187; comparison
p= 0.142; heterogeneity p = 0.045). According to the Cochrane
Handbook [41], heterogeneity among studies resulting in this
analysis was resolved when 2 outlying trials [15,17] were excluded,
fully confirming the results (all trials analysis – OR: 0.546, 95%
CI: 0.393 to 0.759, comparison p= 0.000, heterogeneity
p = 0.151; NT-proBNP analysis – OR: 0.459, 95% CI: 0.319 to
0.661, comparison p= 0.000, heterogeneity p = 0.240; BNP
analysis – OR: 0.819, 95% CI: 0.528 to 1.269, comparison
p= 0.371, heterogeneity p = 0.689).
All-cause hospitalization (Figure 4). Natriuretic peptide-
guided therapy did not reduce significantly all-cause hospitaliza-
tion (OR: 0.803; 95% CI: 0.629 to 1.024; comparison p= 0.077;
heterogeneity p = 0.604)(Figure 3) without heterogeneity among
studies. When separately assessed, neither NT-proBNP-guided
therapy (OR: 0.779; 95% CI: 0.414 to 1.465; comparison
p= 0.438; heterogeneity p= 0.181), nor BNP-guided therapy
(OR: 0.726; 95% CI: 0.509 to 1.035; comparison p= 0.077;
heterogeneity p= 0.836) significantly reduced all-cause hospital-
ization. For this outcome, the effect was dominated by TIME-
CHF trial [16], since after its removal the reduction of all-cause
hospitalization determined by natriuretic peptide-guided therapy
became significant (OR: 0.689; 95% CI: 0.494 to 0.962;
p = 0.029).
Younger vs older patients. Separate outcome analyses on
patients younger or older than 75 years were performed using data
reported in 3 trials [16,17,23]. The composite outcome of all-cause
mortality and HF-related hospitalization was significantly reduced
by natriuretic peptide-guided therapy in younger patients (#75
years)(OR: 0.449; 95% CI: 0.207 to 0.973; p= 0.043), but not in
Figure 2. Odds ratios of all-cause mortality. Solid squares represent odds ratios in trials and have a size proportional to the number of events.
The 95% confidence intervals for individual trials are denoted by lines and those for the pooled odd ratios by empty diamonds.
doi:10.1371/journal.pone.0058287.g002
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investigated the usefulness of natriuretic peptide-guided therapy in
chronic HF [25,26]. These meta-analyses, collecting 6 [13,15–
17,19,22] or 8 [13–20] randomized clinical trials, reported non
definitive results on all-cause mortality and no benefit on
hospitalization afforded by peptide-guided therapy, leading the
recent European Society of Cardiology Guidelines on chronic HF
[2] to consider still uncertain and without recommendations the
use of cardiac peptides to assist management of patients, and the
AHA/ACC HF Guidelines [27] to give a low-level of recommen-
Figure 4. Odds ratios of all-cause hospitalization. Solid squares represent odds ratios in trials and have a size proportional to the number of
events. The 95% confidence intervals for individual trials are denoted by lines and those for the pooled odd ratios by empty diamonds.
doi:10.1371/journal.pone.0058287.g004
Figure 5. One study removed analysis for all-cause mortality. Rows represent the results of meta-analysis of all studies except the omitted
study named in that row.
doi:10.1371/journal.pone.0058287.g005
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Given	 the	 recent	 findings	 of	 the	 PARADIGM-HF	 trial,	 it	 is	 anticipated	 that	 sacubitril-valsartan	 will	
become	an	established	therapy	for	the	treatment	of	chronic	HF.	Clearly	no	trials	have	assessed	the	
use	 of	 B	 type	 natriuretic	 peptide	 monitoring	 in	 patients	 treated	 with	 angiotensin-neprilysin	













chronic	HF,	 there	are	 several	novel	biomarkers	 to	which	assays	are	now	available,	 that	may	prove	
more	useful	in	this	respect.	It	is	the	aim	of	this	MD	to	examine	4	novel	biomarkers,	Mid-Regional	Pro-













Adrenomedullin	 (ADM)	 is	 a	 52-amino	 acid	 peptide	 with	 potent	 endogenous	 vasodilatory	 and	
natriuretic	properties(193).	 	Originally	 isolated	 in	1993	 from	extracts	of	human	phaeochromocytoma	
cells	 in	 the	 adrenal	 medulla(194),	 it	 has	 subsequently	 been	 isolated	 in	 a	 wide	 variety	 of	 tissues	
including	brain,	 lung,	 kidney,	 gastrointestinal	 tract	 and	 the	heart(195).	 It	 shows	27%	homology	with	
calcitonin	 gene	 related	 peptide	 (CGRP)(195)	 and	 as	 such	 belongs	 to	 the	 calcitonin	 superfamily	 of	
peptides.	
	
Reliable	 quantification	 of	 the	 peptide	 itself	 is	 hampered	 by	 both	 its	 short	 plasma	 half-life	
(approximately	 22	 minutes),	 it’s	 binding	 to	 plasma	 proteins	 and	 degradation	 via	 the	 membrane	
metallo-endopeptidase	(MME)	enzyme,	neprilysin.	As	with	the	natriuretic	peptides,	ADM	is	derived	
from	 a	 larger	 precursor	 peptide,	 preproadrenomedullin	 (preproADM).	 By	 post-translational	
processing,	two	smaller	biologically	inactive	proADM	fragments	are	produced:	one	mid-regional	part	
(MRproADM)	and	the	COOH	terminus.	Work	by	Struck	et	al(196)	indicated	that,	compared	with	ADM,	









The	 main	 sites	 of	 production	 of	 ADM	 are	 endothelium	 and	 vascular	 smooth	 muscle(198,	 199).	 Its	












• ADM	 induces	 endothelium	 independent	 relaxation	 by	 acting	 on	 CGRP1	 receptors	 and	
elevating	 cyclic	 adenosine	 monophosphate	 (cAMP)	 levels	 in	 vascular	 smooth	 muscle	
cells.		
• ADM	 secretion	 by	 endothelial	 cells	 may	 function	 as	 an	 endothelium-derived	 relaxing	
factor.		
• ADM	 may	 also	 activate	 potassium	 channels	 in	 smooth	 muscle	 cells	 causing	 cell	
hyperpolarization(201).		
• ADM	binds	 to	specific	 receptors	 in	endothelial	cells	and	elicits	endothelium-dependent	
vasodilatation	 mediated	 by	 nitric	 oxide	 (NO)(202),	 endothelium-derived	 hyperpolarizing	
factor(203),	and/or	vasodilatory	prostanoids(204).		
• ADM	 activates	 endothelial	 nitric	 oxide	 synthase	 (eNOS)	 by	 at	 least	 two	 mechanisms.	
First,	 ADM	 elevates	 intracellular	 calcium	 levels,	 which	 increases	 eNOS	 activity(205).	
Second,	 ADM	 activates	 phosphatidylinositol	 3-kinase	 (PI3K)	 and	 protein	 kinase	 B/Akt,	




Further	 studies	 have	 demonstrated	 the	 ability	 of	 intravenously	 infused	 ADM	 to	 decrease	 cardiac	
preload	 and	 afterload	 and	 improve	 contractility	 of	 the	 myocardium	 with	 a	 resultant	 increase	 in	





consequent	 decrease	 in	 afterload.	 Although	 decreased	 peripheral	 resistance	 and	 blood	 pressure	
induces	reflex	tachycardia,	heart	rate	increases	to	a	lower	extent	than	after	administration	of	other	
vasodilators	 that	 induce	 comparable	 hypotension.	 Combined	 with	 both	 cAMP	 dependent	 and	
independent	 increases	 in	 myocardial	 inotropy(210,	 211)	 the	 net	 result	 is	 one	 of	 increased	 cardiac	
output.	 Further	work	 has	 demonstrated	 its	 release	 from	 the	myocardium(212)	 and	 that	 infusion	 of	






human	 subjects,	 it	 has	 been	 shown	 to	 increase	 plasma	 renin	 concentrations(215)	 but	 selectively	





septic shock patients. They found concentrations of MR-
proADM to be much higher in septic shock patients than in
normal control patients. In a study of 518 healthy volunteers
with a mean age of 61 years, women showed significantly
higher plasma MR-proADM concentrations compared to
men [60]. In multivariate analysis, only age, body mass
index (BMI), and estimated glomerular filtration rate were
independent predictors of plasma MR-proADM concentra-
tions. A possible explanation for the relationship between
increasing BMI and MR-proADM is that ADM has been
shown to be expressed in a number of tissues, particularly
adipose tissue [61]. ADM may serve to protect against the
deleterious effects of increasing BMI and the subsequent
development of metabolic syndrome by promoting vasodi-
lation and insulin sensitivity via paracrine and autocrine
actions [62]. Its effects on insulin resistance and its secretion
by adipose tissue may represent a counter regulatory endo-
crine response to increasing obesity. Dieplinger et al. [63]
reported similar findings about the renal influence on MR-
proADM in patients with nondiabetic chronic kidney dis-
ease [63]. In this study, they observed a continuous increase
in MR-proADM plasma concentrations across glomerular
filtration rate stages. They concluded that the natriuretic and
vasodilator properties of MR-proADM may have a protec-
tive role in the preservation of renal function.
MP-proADM in Acute Coronary Syndrome and Acute
Myocardial Infarction
Patients with acute coronary syndrome are at highest risk to
develop AMI. Over the years, circulating levels of B-type
natriuretic peptide (BNP) and N-terminal pro–B-type natri-
uretic peptide (NT-proBNP) have proved to be strong
prognostic markers in the prediction of death or HF after
an AMI [64–66]. The AtheroGene-Study investigated MR-
proADM concentrations in 2,240 individuals with stable
angina pectoris or with acute coronary syndrome and eval-
uated their prognostic impact on cardiovascular events dur-
ing a follow-up period of almost 4 years [67]. They found
that MR-proADM concentrations were independently asso-
ciated with fatal or nonfatal cardiovascular events. In both
groups, MR-proADM added information beyond that
obtained from classic risk models, essentially equal to that
of NT-proBNP. MR-proADM and its prognostic value in
patients with AMI have been demonstrated in the Leicester
Acute Myocardial Infarction Peptide (LAMP) study by
Khan et al. [14]. Patients with higher levels of MR-
proADM had increased risk for death and HF. Another
important observation was that the prognostic value of
MR-proADM for mortality was better than that of both
BNP and NT-proBNP. Kaplan-Meier analysis showed that
MR-proADM was particularly useful in the group of
patients in whom NT-proBNP was elevated. The authors
conclude that MR-proADM allows a better risk stratification
for patients than it is possible using NT-proBNP alone.
MR-proADM in Acute Heart Failure
Several studies showed that plasma ADM levels were not
only a biochemical marker for evaluating the severity of HF,
but also independent prognostic indicators in patients with
acute or chronic HF [11, 56, 68–70]. Regarding MR-
proADM, Gegenhuber et al. [15] reported in 137 patients
with acute destabilized HF that increased concentration of
MR-proADM indicates an increased risk of future mortality.
High plasma concentrations of MR-proADM predicted 1-
Fig. 2 The actions of
adrenomedullin in acute heart
failure







with	 healthy	 controls(219)	 and	 correlation	 with	 decreasing	 LVEF(220).	 Studies	 have	 attempted	 to	
evaluate	 the	potential	of	MRproADM	for	 the	diagnosis	of	HF	 in	patients	presenting	with	dyspnoea	
but	to	date,	the	ability	of	MRproADM	to	accurately	diagnose	the	condition	remains	inferior	to	that	of	







mortality	 in	 chronic	 HF	 patients	 independent	 of	 other	 established	 prognostic	 factors	 including	
NTproBNP,	LVEF,	NYHA	class,	creatinine	and	age(224).	More	recently,	Adlbrecht	et	al(225)	showed	that	
the	prognostic	 value	of	BNP	was,	 in	 fact,	 inferior	 to	 that	of	MRproADM	 in	 a	 cohort	 of	 over	 seven	





To	 date,	 only	 one	 published	 study	 has	 attempted	 to	 evaluate	 the	 use	 of	 serial	 measurements	 of	
MRproADM.	 In	 this,	 Neuhold	 et	 al	 (227)	 studied	 181	 patients	 with	 a	 recent	 HF	 hospitalisation	
undergoing	 optimisation	 of	 prognostically	 indicated	 medications.	 Their	 results	 indicated	 that	
although	 absolute	 baseline	 and	 follow-up	 concentrations	 of	 BNP	 and	 MRproADM	 were	 equally	





























receptor	but,	at	 the	 time,	no	known	 ligand(229).	 It	 remained	an	“orphan	 receptor”	until	1998	when	
apelin	was	isolated	from	bovine	stomach	extracts(230).		
	
Apelin	 is	 secreted	 as	 a	 77-amino	 acid	 pre-proprotein.	 After	 translocation	 into	 the	 endoplasmic	
reticulum	and	cleavage	of	the	signal	peptide,	the	proprotein	of	55	amino	acids	may	generate	several	
active	 fragments:	 a	36-amino	acid	peptide	 corresponding	 to	 the	 sequence	42-77	 (apelin	36),	 a	17-





The	 expression	of	 apelin	 and	APJ	 is	 regulated	by	multiple	 factors,	 including	hypoxia(232),	 TNF-α(233),	
Ang	 II(234)	 and	 some	 bone	 morphogenic	 proteins(235).	 In	 animal	 models	 of	 HF,	 apelin	 mRNA	 was	
markedly	down	regulated	 in	 rat	myocytes	 subjected	 to	stretch	as	well	as	 in	 two	 further	models	of	







who	 exhibited	 left	 ventricular	 reverse	 remodelling	 and	 an	 increase	 in	 ejection	 fraction	 post	 CRT.	
Furthermore,	 in	murine	models	of	hypertensive	heart	disease,	the	expression	of	cardiac	apelin	and	
APJ	 shows	 no	 change	 at	 the	 stage	 of	 compensatory	 left	 ventricular	 hypertrophy,	 but	 is	markedly	
decreased	at	the	stage	of	HF(237).		
	






A	potent	 inotropic	effect	has	been	demonstrated	 in	vivo	and	ex	vivo	 in	normal	rat	and	mice	hearts	
during	apelin	infusion	of	varying	durations(236,	239-241).	The	exact	mechanism	by	which	apelin	exerts	its	
inotropic	 effects	 remains	 unknown	 however	 this	 is	 believed	 to	 be	 via	 an	 increase	 in	 intracellular	
calcium	 (figure	 18)(238).	 This	 proposal	 is	 supported	 by	 the	 finding	 that	 apelin	 induced	 inotropy	 is	
attenuated	 by	 inhibition	 of	 phospholipase	 C,	 protein	 kinase	 C	 and	 the	 sarcolemmal	 Na+/Ca2+	 and	
Na+/H+	exchangers(240).	
 
patients with chronic pulmonary disease and normal cardiac
function while BNP concentrations remained unchanged [54].
However, in patientswith severe left ventricular dysfunction or
idiopathic pulmonary hypertension apelin was still decreased
but BNPwas raised suggesting that apelinmay be amarker for
chronic pulmonary disease. In patients presenting to an
emergency roomwith dyspnoea, apelin did not reliably predict
acute heart failure and was not a prognostic marker in those
with confirmed heart failure [55]. In patients with chronic heart
failure secondary to idiopathic dilated cardiomyopathy,
plasma apelin was no different to normal controls unlike the
other biomarkers which included NT-proBNP, IL-6, TNF-α
and norepinepherine [56]. Unlike the biomarker BNP, which
can be used as a diagnostic screening test and prognostic
marker for heart failure, current data does not suggest a similar
application for apelin.
4.5. Apelin in atherosclerosis
There is a small amount of evidence that the apelin–APJ
system may be involved in modulating endothelial oxidative
stress and the formation of coronary atherosclerotic plaques.
In APJ and ApoE double knock-out mice fed a high
cholesterol diet, atherosclerotic plaque burden was consider-
ably reduced compared with single ApoE knock-out mice
without any difference in cholesterol concentrations [57].
There was also a reduction in markers of oxidative stress and
vascular smooth muscle cells in the double knock-out mice.
However, in humans with hypercholesterolaemia, plasma
apelin was decreased compared to matched controls [58] and
there was no increase in the expression of APJ receptors in
atherosclerotic vessels compared to normal controls [59].
4.6. Apelin and cardiac conduction
Apelin may well have an important role to play in cardiac
electrophysiology. A recent study has shown that high
concentrations of apelin are found around the intercalating
discs that are vital to cellular electrical coupling [42]. In this
study apelin increased the frequency of spontaneous activa-
tion, conduction velocity and reduced the field potential
duration in monolayers of cultured neonatal rat cardiomyo-
cytes. In a large animalmodel therewas evidence of high grade
AV block in 50%, which was not observed in smaller animals
raising concerns about the use of supraphysiological doses of
apelin for therapy [15]. Apelin levels have been shown to be
raised in patients without structural heart disease and in sinus
rhythm, who have a history of lone atrial fibrillation [60].
However, the true significance of this finding and the
relationship between medication usage and timing of previous
cardioversion require further investigation, therefore the role
of apelin in human arrhythmogenesis is unknown.
4.7. Apelin and the cardiorenal axis
Heart failure and renal failure are inextricably intertwined
giving rise to the term “cardiorenal syndrome”. The actions of
the RAS directly affect the kidney and therefore a link between
renal disease and the apelin–APJ system seems entirely
plausible. In haemodialysed patients without heart failure
symptoms, the concentration of apelin-36 was lower in
patients with coexisting coronary artery disease and correlated
with diastolic LV dimensions [61]. In another study by a
different group, apelin was found to be lower in dialysed
uraemic patients, most of whom had systolic dysfunction,
compared to patients with dilated cardiomyopathy (DCM)
with normal renal function [62]. This observation was
independent of cardiac function despite the DCM patients
having lower ejection fractions. Apelin has also been shown to
regulate renal arterial tone in diabetic mice by modulating the
vascular responsiveness toAng II and by increasing generation
of NO by endothelial NOS [63]. It is well documented that
cardiovascular disease is a major cause of mortality and
morbidity in patients with end-stage renal disease. Although
further work is needed, there may well be a link between the
apelin–APJ system and the pathogenesis of cardiovascular
disease in chronic renal disease, which opens up the possibility
of apelin as a therapeutic agent in these patients.
Fig. 2. The role of apelin in heart failure. Ang II = Angiotensin II AT1 = angiotensin-II type one receptor. NO = nitric oxide.
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Calcium	 reuptake	 is	 mediated	 by	 the	 energy	 requiring	 sarcoendoplasmic	 reticulum	 Ca2+-	 adenosine	 triphosphatase	
(SERCA2A)	 and	 Phospholamban	 (P),	 which	 in	 turn	 allows	 relaxation.	 Apelin	 activates	 protein	 kinase	 C	 (PKC)	 and	
phospholipase	C	(PLC)	that	acts	on	the	sarcolemmal,	Na+-H+	exchanger	(NHE)	to	increase	intracellular	Na+	resulting	in	an	











Studies	 looking	 at	 the	 use	 of	 apelin	 to	 aid	 diagnosis	 of	 HF	 have,	 to	 date,	 been	 disappointing.	 In	







concentrations	were	 unable	 to	 distinguish	 patients	with	 known	 idiopathic	 dilated	 cardiomyopathy	
from	a	control	group	and	had	no	relationship	to	the	level	of	cardiac	dysfunction(244).	Evidence	from	












reverse	 remodelling(247).	 Furthermore,	 plasma	 apelin	 has	 been	 shown	 to	 increase	 in	 patients	with	

















in	 1989(249).	 It	 exists	 in	 two	 distinct	 forms;	 a	 transmembrane	 form	 –	 the	 ST2	 ligand	 (ST2L),	 and	 a	
soluble,	circulating	form	(sST2).	These	isoforms	result	from	alternative	splicing	and	3’	processing	of	




helper	 cells	 and	 the	production	of	 Th2-associated	 cytokines(250).	 	A	 cardiovascular	 role	 for	 ST2	was	
not	suggested	until	2002	when	Weinberg	et	al,	demonstrated	up-regulation	of	both	isoforms	of	ST2	
by	mechanically	 stressed	 cardiomyocytes	 and	 fibroblasts	 in	 an	 in	 vitro	 model(251).	 It	 was	 not	 until	





33/ST2L	pathway	works	as	part	of	a	 cardioprotective	 signalling	 system	that	 regulates	 responses	of	
the	 ventricular	 myocardium	 to	 altered	 loading	 conditions,	 including	 myocyte	 hypertrophy	 and	
fibrosis(253).	One	possible	mechanism	by	which	ST2	may	exert	its	effects	was	proposed	by	Seki	et	al,	
who	 demonstrated	 decreased	 caspase-3	 activation,	 a	 critical	 step	 in	 apoptosis,	 and	 increased	
expression	 of	 the	 anti-apoptotic	 gene	 Bcl-2	 in	 rat	 cardiomyocytes	 exposed	 to	 IL-33	 in	 vitro.	 Such	
proposals	 have,	 to	 date,	 yet	 to	 be	 fully	 established.	 Despite	 this,	 however,	 derangement	 of	 the	
signalling	 system	 has	 been	 consistently	 demonstrated	 to	 result	 in	 a	 phenotype	 consistent	 with	
myocardial	remodelling	in	patients	with	chronic	HF,	supporting	its	proposed	pathophysiological	role.	
In	 an	 in	 vivo	model	 of	 ventricular	 pressure	 overload,	mice	 subjected	 to	 partial	 aortic	 constriction	











In	 this	 way,	 it	 is	 proposed	 to	 act	 as	 a	 ‘decoy’	 receptor.	 Indeed,	 in	 the	 face	 of	 exogenous	 pro-
hypertrophic	 stimuli	 such	 as	 Ang	 II,	 IL-33	 administration	 to	 cultured	 rat	 cardiomyocytes	 results	 in	
attenuation	of	cellular	hypertrophy.	If	sST2	is	added	to	the	cell	culture	media,	however,	these	effects	
of	 IL-33	 are	 not	 only	 abolished,	 but	 reversed(253).	 It	 is	 thought,	 therefore,	 that	 sST2	 in	 the	
extracellular	 environment	 acts	 by	 binding	 free	 IL-33,	 thereby	 effectively	 decreasing	 the	
concentration	of	 IL-33	 that	 is	available	 for	ST2L	binding,	 reducing	 the	biological	effect	of	 IL-33	and	
modulating	IL-33/ST2L	signalling.	
	
It	 is	 the	 soluble	 form,	 sST2,	 to	 which	 assays	 are	 available.	 Currently,	 however,	 there	 are	 only	 a	
limited	number	of	enzyme-linked	immunosorbent	assays	(ELISA)	for	the	detection	and	measurement	
of	sST2.	Early	assays	suffered	from	low	sensitivity	and	poor	analytical	coefficient	of	variation	(CVa).	
More	 recently,	 the	 ‘Presage	 ST2Ò’,	 a	 highly	 sensitive	 ELISA	 for	 sST2	 has	 been	 developed	 and	
validated	in	a	large	cohort(254).	Interestingly,	although	ST2	is	associated	with	allergic	and	immunologic	
diseases	 such	 as	 asthma,	 among	 subjects	 with	 normal	 heart	 function,	 sST2	 was	 not	 found	 to	 be	
higher	 in	 those	with	 such	 underlying	 conditions.	 In	 addition,	 unlike	 the	 natriuretic	 peptides,	 sST2	









of	 Dyspnea	 in	 the	 Emergency	 Department	 (PRIDE)	 study(255).	 In	 this	 study	 looking	 at	 593	 patients	
admitted	 to	 the	 emergency	 department	with	 acute	 dyspnoea,	 sST2	 concentrations	were	 higher	 in	
those	with	 HF	 than	 those	with	 non-cardiac	 breathlessness.	Moreover,	 there	was	 a	 concentration-
dependent	relationship	between	sST2	and	risk	of	death	at	one	year,	with	its	prognostic	value	being	




Experiments	 looking	 at	 serum	 sST2	 following	 the	 induction	 of	myocardial	 infarction	 first	 indicated	
the	 potential	 of	 sST2	 as	 a	 biological	 marker	 for	 mechanical	 overload	 in	 the	 heart.	 In	 patients	
presenting	with	ST-elevation	myocardial	 infarction	 (STEMI),	 sST2	 levels	at	 the	 time	of	presentation	
correlated	 with	 the	 incidence	 of	 in-hospital	 and	 thirty-day	 mortality(256).	 Given	 that	 mechanical	
overload	of	the	myocardium	is	a	feature	of	many	types	of	HF,	Weinberg	et	al	further	demonstrated	
that	sST2	levels	in	patients	with	non-ischaemic	HF	not	only	correlated	with	serum	BNP	levels	but	also	





Ky	 et	 al(262),	 in	 a	 study	 of	 1141	 outpatients	 with	 a	 clinical	 diagnosis	 of	 HF	 demonstrated	 an	
independent	 association	 between	 single	 baseline	 measurements	 of	 sST2	 and	 risk	 of	 adverse	
outcomes.	Gruson	et	al(263)	have	reported	similar	findings	with	an	association	between	baseline	sST2	
and	CV	mortality	 in	 a	 sample	of	137	outpatients	with	 reduced	 LVEF	 treated	with	optimal	 therapy.	
More	 recently,	 Sobczak	 et	 al(264)	 have	 demonstrated	 the	 ability	 of	 single	 baseline	 sST2	 to	 predict	
















week	 sampling	 period	 was	 predictive	 of	 cardiac	 events	 (including	 death,	 HF	 admission	 and	 heart	
transplantation)	 at	 one	 year.	More	 recently,	 however,	Manzano-Fernandez	 et	 al(260),	 in	 a	 study	 of	
seventy-two	 acute	 HF	 patients,	 found	 that	 sST2	 concentrations	 at	 presentation	 had	 a	 greater	
prognostic	 accuracy	 for	 two-year	mortality	 than	 percentage	 change	 in	 sST2	 between	baseline	 and	
four	 days.	 	 In	 the	 largest	 series	 to	 date,	 Breidthardt	 et	 al(258)	 examined	 changes	 in	 sST2	















revealed	 the	 RCV	 of	 sST2	 in	 healthy	 volunteers	 to	 be	 30%	 -	 much	 lower	 than	 that	 of	 the	 B-type	
natriuretic	peptides.	 In	 support	of	 this	 finding,	Breidthardt(267)	 reported	a	decrease	 in	 sST2	greater	
than	 50%,	 in	 response	 to	 the	 initiation	of	HF	 therapy,	was	 associated	with	 a	 significantly	 less	 one	
year	mortality	rate	than	in	those	with	less	than	a	50%	decrease	in	sST2	(11%	vs	41%	respectively).		
	
Despite	such	promising	 results,	 it	 is	 likely	 that	variation	amongst	patients	with	disease	 reflects	 the	



























and	 mitochondria.	 When	 secreted	 into	 the	 extracellular	 space,	 in	 can	 interact	 with	 cell	 surface	





is	 rapid	 up-regulation.	 Although	 the	 exact	 myocardial	 localisation	 of	 galectin-3	 has	 yet	 to	 be	
definitively	 established,	 immunochemistry	 of	 hypertrophied	 rat	 myocardium	 has	 demonstrated	
binding-sites	 localised	 predominately	 in	 the	 myocardial	 matrix,	 fibroblasts	 and	 macrophages(268).	
Moreover,	 in	 proliferating	 fibroblasts	 of	 the	 same	 hypertrophied	 hearts,	 these	 binding-sites	 were	
localised	 around	 the	 nucleus,	 with	 only	 minimal	 cytoplasmic	 binding	 sites	 observed	 in	 resting	
fibroblasts,	 suggesting	 that	 galectin-3	may	 induce	 cardiac	 fibroblast	 proliferation(268).	 Furthermore,	




Fibroblasts	 and	macrophages	 are	 key	 cells	 in	 the	 initiation	 and	 progression	 of	 fibrosis	 and	 tissue	
scarring.		Up-regulation	of	galectin-3	has	been	demonstrated	in	animal	models	of	hepatic,	renal	and	










there	 is	 no	 definitive	 evidence	 that	 a	 causal	 relationship	 exists	 between	 galectin-3	 and	 the	




Several	 studies	have	examined	 the	use	of	 galectin-3	as	 a	biomarker	 for	HF	diagnosis(243,	 273,	 274).	 To	
date,	 such	 studies	 have	 indicated	 that	 galectin-3	 is	 inferior	 to	 the	 natriuretic	 peptides	 for	 this	
purpose.	 Using	 data	 from	 the	 Pro-BNP	 Investigation	 of	 Dyspnea	 in	 the	 Emergency	 Department	
(PRIDE)	study(169),	 van	Kimmenade	et	al	demonstrated	that	NTproBNP	was	significantly	better	 than	
galectin-3	 for	 the	 diagnosis	 of	 HF	 (AUC	 0.94	 vs	 0.72	 respectively;	 p<0.0001)(243).	 More	 recently,	
Mueller	 et	 al	 have	 corroborated	 these	 findings,	 demonstrating	 an	AUC	of	 0.92	 for	 BNP	 compared	
with	 0.57	 for	 galectin-3	 for	 the	 diagnosis	 of	 HF	 in	 251	 patients	 presenting	 to	 the	 emergency	
department	with	acute	dyspnoea(274).	Moreover,	the	addition	of	galectin-3	to	BNP	did	not	add	to	the	
diagnostic	 capability	 of	 BNP,	 nor	 were	 increased	 levels	 of	 galectin-3,	 defined	 as	 >25.9ng/ml,	
independently	associated	with	the	diagnosis	of	acute	HF(274).		
	
	One	 possible	 explanation	 for	 these	 findings	 relates	 to	 the	 proposed	 relationship	 of	 galectin-3	 to	
fibrosis	and	scarring.	Given	that	these	phenomena	are	presumed	to	be	relatively	late	manifestations	















department,	 Shah	et	al(280)	demonstrated	 that,	although	galectin-3	 levels	were	not	associated	with	






a	 study	 by	 Motiwala	 et	 al(136),	 using	 patients	 enrolled	 in	 the	 PROTECT	 trial,	 additional	 galectin-3	
sampling	at	six	months	provided	significantly	greater	prognostic	information	that	that	of	the	baseline	
level	 alone.	Moreover,	 they	 demonstrated	 that	 an	 increase	 of	 ≥15%	 at	 any	 of	 the	 three-monthly	
review	time	points	conferred	worse	prognosis,	even	after	extensive	clinical	adjustments.	This	finding	
was	also	noted	by	van	der	Velde	and	colleagues(137).	Using	the	Val-HEFT	population,	Anand	et	al(282)	
showed	 that,	 over	 a	 four-month	 follow-up,	 for	 every	 1ng/ml	 increase	 in	 galectin-3,	 there	 was	 an	
associated	2.9%	increase	in	risk	of	mortality	(p=0.008)	and	a	2.1%	increased	risk	of	first	morbid	event	
(p=0.03).	To	date,	however,	no	studies	have	been	able	to	demonstrate	any	effect	on	galectin-3	levels	









subjects(266,	 283).	 In	 a	 study	 on	 seventeen	 healthy	 subjects,	 Wu	 et	 al(266)	 reported	 intra-individual	
coefficient	 of	 variation	 of	 galectin-3	 of	 16%	at	 one	hour	 and	 20%	at	 two	months.	 This	 resulted	 in	
computed	reference	change	values	of	39%	and	61%	respectively,	significantly	lower	than	that	of	the	
natriuretic	peptides,	but	higher	than	that	of	sST2.	More	recently,	Franekova	et	al(283)	have	reported	
on	a	 series	of	44	patients	 followed	 for	12	months	post	heart	 transplant.	 In	 this	 study,	 the	authors	
report	a	one-year	 intra-individual	 coefficient	of	variation	of	28.2%,	giving	an	overall	RCV	of	78.6%.	
Using	 their	 results	 RCVs	 for	 both	 increase	 and	 decrease	 in	 galectin-3	 concentrations	 were	 also	
calculated	at	116%,	and	–53.7%,	respectively,	leading	the	authors	to	conclude	that	the	concentration	


















1. Measure	 the	biological	variability	 in	patients	with	stable	chronic	HF	at	 several	 time	points:	
one	 hour,	 one	month,	 three	months	 and	 six	months	 and	 compare	 with	 NTproBNP	 in	 the	
same	cohort.	
2. Calculate	 the	 reference	 change	 values	 at	 one	hour,	 one	month,	 three	 and	 six	months	 and	
compare	these	with	the	RCV	of	NTproBNP	in	the	same	cohort.		
3. Perform	 ROC	 analyses	 to	 assess	 the	 ability	 of	 the	 novel	 biomarkers	 to	 predict	 HF	
decompensation.	
4. Perform	 a	 multi-marker	 comparison	 to	 assess	 the	 added	 value	 of	 combining	 markers	 in	
predicting	outcome	in	chronic	HF.	
	
By	 assessing	 the	 putative	 value	 of	 these	 biomarkers,	my	 hypothesis	 is	 that	 one	 or	more	 of	 these	
novel	biomarkers	will	have	a	RCV	lower	than	that	of	NTproBNP.	 In	addition,	 it	 is	hypothesised	that	
the	percentage	and/or	absolute	changes	over	time	will	be	better	than	that	of	NTproBNP	in	predicting	
HF	decompensation,	defined	as	a	CV	admission	during	the	study	period.	This	being	so,	it	would	then	








































The	 primary	 endpoint	 of	 the	 study	 was	 CV	 admission,	 defined	 as	 an	 admission	 due	 to	
decompensated	HF,	arrhythmia	or	acute	coronary	syndrome.	Justification	for	this	endpoint	is	based	
on	 previous	 work	 (as	 cited	 in	 section	 1).	 Given	 the	 small	 sample	 size,	 a	 composite	 endpoint	 was	
deemed	most	 suitable	 to	 capture	 sufficient	 events	 for	 statistical	 analysis.	 Associations	with	ADHF,	



























All	 study	 participants	 had	 undergone	 transthoracic	 echocardiography	 (TTE)	 within	 six	 months	 of	
recruitment.	The	echocardiography	department	at	King’s	College	Hospital	performed	all	scans	with	
iE33	 echocardiography	 machines	 (Philips	 Medical	 Systems,	 Andover,	 Massachusetts).	 Images	





Phillips).	 Each	 study	was	performed	and	 reported	 in	 accordance	with	 the	 European	Association	of	



















MRproADM	 analysis	 was	 performed	 using	 a	 novel	 automated	 sandwich	 chemiluminescence	
immunoassay	(BRAHMS),	which	utilises	a	purified	sheep	polyclonal	preproADM	specific	(amino	acids	














Based	 on	 recent	 publications	 a	 calculated	 cut	 off	 >1.5	 nmol/L	 indicates	 an	 individual	 high	 risk	




Concentrations	 of	 apelin	 were	 determined	 using	 a	 commercially	 available	 enzyme	 immunoassay	
(EIA)	 without	 extraction	 (Phoenix	 Pharmaceuticals),	 the	 use	 of	 which	 has	 been	 described	






sST2	 was	 measured	 by	 enzyme	 linked	 immunosorbent	 assay	 (ELISA)	 (R&D	 Systems	 Europe,	 Ltd.,	
Abingdon,	 UK).	 The	 sST2	 assay	 contains	 NS0-expressed	 recombinant	 human	 sST2	 and	 has	 been	


















Creatinine	 was	measured	 using	 the	 Jaffé	 reaction	 using	 reagents	 supplied	 by	 Siemens	 Healthcare	
Diagnostics	 Ltd,	 Camberley,	 Surrey,	 UK.	 The	 initial	 rate	 of	 absorbance	 change	 is	 measured	 at	 a	
wavelength	of	505	nm	and	compared	to	that	of	a	known	calibrant.	This	is	directly	proportional	to	the	
concentration	 of	 creatinine	 in	 the	 sample.	 A	 blank	 reaction	 rate	 is	 performed	 using	 reagent	 1	









Serum	 electrolytes	 were	 measured	 using	 the	 Siemens	 Advia	 2400	 analyser	 with	 ion	 selective	
electrode	(ISE)	reagent	supplied	by	Siemens	Healthcare	Diagnostics	Ltd,	Camberley,	Surrey,	UK.		
The	serum	sample	 is	mixed	with	 ISE	buffer	 (1:33	dilution)	to	provide	a	constant	pH	and	a	constant	
ionic	strength	solution.	As	the	buffered	sample	flows	past	the	electrode	a	new	equilibrium	forms	due	











The	 Siemens	Advia	 2120i	was	used	 to	 analyse	 the	 full	 blood	 count	 (FBC)	 using	 reagents	 supplied	 by	




Method	 1:	 a	 cyanide	 free	 colourimetric	 method,	 which	 lyses	 the	 RBC	 to	 release	 the	
haemoglobin.	The	haem	ion	is	oxidised	to	the	ferric	state	where	it	combines	with	the	reagent	to	




Method	2:	 Cellular	HGB	 is	 a	 calculated	method	which	uses	 the	directly	measured	parameter	




The	 2	 methods	 should	 not	 differ	 by	 more	 than	 1.9g/dl	 however	 if	 they	 do	 an	 error	 message	 is	
flagged.	 The	 CHCM	 is	 only	 used	when	 the	 haemoglobin	 is	 falsely	 increased	 and	 the	MCHC	 is	 also	







Total	 bilirubin	 was	 calculated	 using	 the	 Siemens	 Advia	 2400	 assay	 using	 reagents	 supplied	 by	
Siemens	Healthcare	Diagnostics	 Ltd,	Camberley,	 Surrey,	UK.	The	principle	of	 the	assay	 is	based	on	
the	fact	that	bilirubin	reacts	under	acidic	conditions	with	vanadate	ions,	resulting	in	its	oxidation	to	








The	 initial	 hypothesis	 of	 this	 study	 was	 aimed	 at	 examining	 the	 biological	 variability	 of	 novel	
biomarkers	compared	with	the	natriuretic	peptides.	As	there	had	been	no	longitudinal	studies	which	



































































































where	 Z	 (the	 95%	 confidence	 interval	 Z	 score)	 is	 1.96.	 This	 level	 of	 RCV	 reflects	 the	 minimum	










































































































were	 treated	 with	 CRT.	 One	 patient	 had	 been	 offered	 CRT	 but	 had	 declined	 at	 the	 time	 of	
recruitment.	All	the	remaining	6	patients	had	QRS	morphology	of	<150ms.	Two	demonstrated	a	right	
bundle	branch	block	(RBBB)	pattern	on	their	ECG	and	had	no	device	in	situ,	two	demonstrated	a	non-







Four	 patients	 withdrew	 from	 the	 study	 prior	 to	 completion	 of	 six-month	 follow-up.	 Reasons	 for	
withdrawal	 for	 consent	 included;	 one	 patient	 who	 was	 non-contactable	 after	 recruitment,	 two	
patients	who	decided	 the	 follow-up	 regime	was	not	 possible	 due	 to	 limitations	 in	mobility	 and/or	
transport	and	one	patient	who	 left	 the	country	due	 to	a	 family	emergency	abroad.	Three	patients	
who	withdrew	were	followed	up	at	the	end	of	the	study	period.	The	medical	records	of	the	patient	
who	remained	uncontactable	were	obtained	and	the	primary	care	physician	was	contacted	to	assess	
for	evidence	of	any	of	 the	study	endpoints.	All	available	results	were	 included	 in	the	final	analysis.	













1	 1	 41	 Fluid	overload	





4	 1	 68	 Fluid	overload	secondary	to	ACS	–	treated	with	PCI	
5	 1	 26	 Fluid	overload	secondary	to	ACS	–	treated	with	
CABG/Mitral	Valve	Repair		
6	 1	 13	 Fluid	overload	secondary	to	ACS	–	medically	managed	
7	 1	 156	 Fluid	overload	







	 CV	Admission	 No	CV	Admission	 p	value	
Clinical	 	 	 	
Age,	mean	(SD;	Range)	 68.13	(12.61;	50-87)	 67.10	(11.52;	45-86)	 0.820	

















Body	mass	index,	mean	(SD;	Range)	 30.50	(5.66;	24-40)	 29.88	(5.72;	20-45)	 0.780	
Hypertension,	n	(%)	 3	(37.5)	 22	(52.4)	 0.445	
Diabetes,	n	(%)	 1	(12.5)	 7	(16.7)	 0.771	
Ischaemic	heart	disease,	n	(%)	 4	(50)	 20	(47.6)	 0.903	
Atrial	fibrillation,	n	(%)	 2	(25)	 10	(23.8)	 0.943	
QRS	(ms),	mean	(SD;	Range)	 139	(44.64;	88-213)	 129	(37.43;	75-222)	 0.478	
CRT,	n	(%)	 2	(25)	 12	(28.6)	 0.838	
ICD,	n	(%)	 4	(50)	 14	(33.3)	 0.333	
NYHA	I,	n	(%)	 0	(0)	 5	(11.9)	 0.309	
NYHA	II,	n	(%)	 6	(75)	 29	(69)	 0.739	
NYHA	III,	n	(%)	 2	(25)	 8	(19)	 0.703	
eGFR,	mean	(SD;	Range)	 61	(20.10;	26-91)	 65	(17.64;	31-91)	 0.613	
Na+,	mean	(SD;	Range)	 139	(1.69;	137-141)	 138	(3.31;	129-143)	 0.543	
Hb,	mean	(SD;	Range)	 13.1	(1.44;	11.4-15.9)	 13.8	(1.40;	10.9-17.4)	 0.164	
Medication	 	 	
ACE-I,	n	(%)	 5	(62.5)	 32	(76.2)	 0.423	
ARB,	n	(%)	 3	(37.5)	 10	(23.8)	 0.423	
β-blocker,	n	(%)	 7	(87.5)	 38	(90.5)	 0.799	
MRA,	n	(%)	 7	(87.5)	 27	(64.3)	 0.202	
Digoxin,	n	(%)	 2	(25)	 6	(14.3)	 0.453	
Regular	Loop	Diuretics,	n	(%)	 8	(100)	 29	(69)	 0.070	
Echo	 	 	
EF,	mean	(SD;	Range)	 27	(6.25;	19-36)	 31	(6.68;	14-40)	 0.116	





































































This	 study	 attempts	 to	 address	 this	 gap	 in	 knowledge	 by	 calculating	 the	 biological	 variability	 of	












The	 distributions	 of	 all	 results	 for	 NTproBNP	 and	 MRproADM	 were	 non-parametric.	 Median	
concentrations	of	NTproBNP	and	MRproADM	at	each	visit	 are	detailed	 in	 table	12.	There	were	no	
significant	differences	in	median	values	from	baseline	across	any	time	point	for	NTproBNP	(one	hour	
p=0.874,	one	month	p=0.883,	three	months	p=0.144,	six	months	p=0.279).	Compared	with	baseline,	
no	 significant	 difference	was	 found	 for	median	MRproADM	concentrations	 at	 one	hour	 (p=0.074),	

















































CVg,	 CVi,	 index	 of	 individuality	 and	 corresponding	 reference	 change	 values	 for	 NTproBNP	 and	
MRproADM	at	each	time	point	are	shown	in	table	13.		
	 1	Hour	 1	Month	 3	Months	 6	Months	
NTproBNP	 MRproADM	 NTproBNP	 MRproADM	 NTproBNP	 MRproADM	 NTproBNP	 MRproADM	
CVi	 18.47	 14.09	 36.75	 13.11	 40.98	 14.04	 46.02	 18.93	
CVg	 28	 48	 28	 42	 32	 38	 32	 63	
II	 0.65	 0.29	 1.31	 0.31	 1.28	 0.37	 1.44	 0.30	
RCV	
(%)	





Paired	 t-tests	were	used	 to	examine	differences	 in	CVi	across	 the	 time	points.	Compared	with	one	
hour	CVi,	significant	variability	was	seen	across	all	time	points	for	NTproBNP;	one	hour	to	one	month	











5.4.3	 Individual	 Coefficients	 of	 Variation,	 Index	 of	 Individuality	 and	 Reference	 Change	 Values:	
Stable	Patients	
CVg,	 CVi,	 index	 of	 individuality	 and	 corresponding	 reference	 change	 values	 for	 NTproBNP	 and	
MRproADM	at	each	time	point	were	re-calculated	after	removal	of	any	patients	reaching	the	primary	
end-point	of	the	study.	Results	are	shown	in	table	14.		
	 1	Hour	 1	Month	 3	Months	 6	Months	
NTproBNP	 MRproADM	 NTproBNP	 MRproADM	 NTproBNP	 MRproADM	 NTproBNP	 MRproADM	
CVi	 18.47	 14.09	 36.15	 12.65	 41.54	 12.41	 42.92	 11.93	
CVg	 28	 48	 29	 37	 32	 38	 34	 30	
II	 0.65	 0.29	 1.25	 0.34	 1.28	 0.33	 1.39	 0.39	
RCV	
(%)	




Paired	 t-tests	 were	 used	 to	 examine	 differences	 in	 CVi	 across	 the	 time	 points.	 After	 removal	 of	
patients	experiencing	a	CV	admission,	variability	 for	NTproBNP	remained	significant	across	all	 time	




















LVEF	 (p=0.001),	 end	 diastolic	 volume	 (EDV)	 (p=0.011),	 duration	 of	 QRS	 complex	 on	 12	 lead	 ECG	
(p=0.008),	NYHA	class	(p=0.042),	creatinine	(p=0.006)	and	eGFR	(p=0.012).	MRproADM	significantly	



































The	 value	 of	 relative	 changes	 in	 both	 NTproBNP	 and	 MRproADM	 were	 assessed	 by	 considering	
absolute	 and	 percentage	 changes	 from	baseline	 to	 follow-up	measurement.	Median	 (Interquartile	
Range	 (IQR))	 percentage	 changes	 for	 the	 group	 overall	 and	 for	 those	 with	 and	 without	 a	 CV	
admission	 are	 shown	 in	 table	 16.	 A	 lower	 MRproADM	 was	 observed	 in	 those	 experiencing	 a	 CV	
admission	at	one	month	and	 three	months,	however	no	 statistical	 significance	was	demonstrated.	
Boxplot	 analyses	 (figures	21	and	22)	of	percentage	 change	 in	MRproADM	and	NTproBNP	over	 the	



























Baseline	 	 50	 -	 -	 -	 -	 -	 -	
	 	 -	 	 -	 	 -	 -	















































































































Similar	 results	 were	 seen	 for	 percentage	 change	 in	MRproADM	 and	 NTproBNP	 at	 three	months	
with	 AUC	 0.659;	 95%	 CI	 0.506	 to	 0.812;	 p=0.362	 vs.	 AUC	 0.651;	 95%	 CI	 0.217	 to	 1.00;	 p=0.386.	
Percentage	change	 in	MRproADM	and	worsening	 renal	 function	at	 six	months,	however,	 showed	












In	 contrast	 to	NTproBNP,	MRproADM	does	not	exhibit	 significant	 variation	either	 in	 the	 short	or	
long	 term	 with	 RCVs	 ranging	 from	 41%	 to	 54%,	 compared	 with	 52%	 to	 128%	 for	 NTproBNP.		
However,	after	 removal	of	all	patients	who	experienced	a	CV	admission,	 results	did	demonstrate	
significant	differences	 in	 the	 calculated	RCVs	 for	MRproADM	between	one	hour	 and	 six	months.	
Clearly	whilst	 this	 could	have	 implications	 for	 serial	monitoring,	 it	 is	unlikely	 that	any	monitoring	
policy	would	 include	sampling	at	 time	points	as	 short	as	one	hour.	Although	not	assessed	 in	 this	
study,	 it	 would	 be	 necessary	 to	 evaluate	 BV	 and	 RCV	 at	 a	minimum	 of	 two	weeks,	 the	 current	
recommended	 follow-up	 time	 post	 discharge	 following	 acute	 decompensation	 in	 the	 UK(302),	 in	
order	to	establish	reliable	BV	components.	Given	that	serial	monitoring	is	unlikely	to	take	place	at	
time	points	of	one	hour,	 this	 finding	 is	unlikely	 to	detract	 from	the	potential	 for	monitoring	 that	
these	 results	 imply.	 Further	 support	 for	 this	 can	 be	 taken	 from	 the	 low	 index	 of	 individuality	 of	
MRproADM,	 indicating	 significant	 differences	 between	 individuals	 relative	 to	 the	 population.	
Consequently,	 single	 concentrations	 cannot	 be	 effectively	 compared	 to	 a	 population-based	




Results	 from	 the	 monitoring	 aspect	 of	 the	 study,	 however,	 did	 not	 prove	 this	 to	 be	 the	 case.	
Despite	significantly	lower	biological	variability	and	references	changes	values	than	NTproBNP,	and	











More	 recently,	 reports	 from	 the	 VERDY	 trial	 showed	 that,	 in	 441	 patients	 presenting	 with	
dyspnoea,	 changes	 in	 MRproADM	 over	 72hrs	 during	 hospitalisation	 were	 non-significant	 for	
predicting	events	at	30	and	90-day	follow-up(303).	However,	of	these,	only	27%	were	known	chronic	





own	 and	 previous,	 much	 smaller,	 studies.	 It	 should	 be	 noted,	 however,	 that	 this	 trial	 made	 no	
attempt	 to	 classify	 LVSD	and,	more	 importantly,	 actively	 excluded	 any	patients	with	 known	EF	 <	
25%.		
	
One	 potential	 signal	 towards	 a	 positive	 result	 is	 seen	 with	 changes	 in	 MRproADM	 and	 renal	
function.	 Over	 the	 six-month	 study	 period,	 percentage	 change	 in	MRproADM	was	 shown	 to	 be	
associated	with	deterioration	in	renal	function,	defined	as	a	≥25%	increase	in	creatinine.	Although	
this	 result	 failed	to	reach	statistical	 significance,	previous	studies	of	MRproADM	have	 indicated	a	
likely	 relationship	 with	 renal	 function,	 which	 would	 be	 consistent	 with	 this	 result(300,	 301,	 305-308).	
Moreover,	results	from	the	study	presented	here	demonstrate	that	concentrations	of	MRproADM	
at	 each	 time	 point	 were	 strongly	 positively	 correlated	with	 both	 creatinine	 and	 eGFR.	 Although	
neither	changes	in	creatinine	or	eGFR	were	predictive	of	CV	admission,	renal	dysfunction	per	se	is	a	
well-recognised	prognostic	marker	in	HF(309-315)	and	the	ability	to	detect	sub-clinical	changes	which	
do	 not	 result	 in	 admission	 but	 are	 prognostic	 with	 respect	 to	 long	 term	 outcomes	 may	 have	
significant	 benefits	 in	 terms	 of	 monitoring	 patients	 who	 are	 otherwise	 fully	 optimised.	 Further,	








in	MRproADM	are	poor	predictors	of	 CV	admission	 in	patients	with	pharmacologically	 optimised	
stable	chronic	HF.	Results	of	this	study	reveal	it	may	be	worse	than	that	of	NTproBNP,	and	as	such	
an	 unattractive	 marker	 for	 future	 use	 as	 a	 monitoring	 tool	 for	 this	 purpose.	 MRproADM	 may,	
however,	 have	 uses	 for	 detecting	 changes	 in	 renal	 function	 prior	 to	 such	 changes	 resulting	 in	
















Studies	 examining	 the	 use	 of	 apelin	 as	 a	 biomarker	 of	 HF	 have	 produced	mixed	 results.	Whilst	
several	 studies	have	demonstrated	 reduced	plasma	and	myocardial	 apelin	 levels	 in	patients	with	
advanced	HF(245,	 247,	 248,	 290,	 316-318),	plasma	apelin	 concentrations	do	not	appear	 to	be	predictive	of	
outcome	 in	 such	 patients(319).	 Moreover,	 other	 studies	 have	 failed	 to	 show	 any	 significant	
difference	 in	 plasma	apelin	 concentrations	 between	patients	with	 stable	 dilated	 cardiomyopathy	
and	 normal	 controls(244)	 or	 in	 those	 presenting	with	 acute	 HF(243).	 No	 studies	 have	 attempted	 to	
assess	the	biological	variability	of	apelin,	or	assess	serial	measurements	for	monitoring	potential.		
	
This	 study	 is	 the	 first	 to	 examine	 the	 calculated	 biological	 variability	 with	 the	 ability	 of	 serial	












The	 distributions	 of	 all	 results	 for	 NTproBNP	 and	 apelin	 were	 non-parametric.	 Median	
concentrations	 of	 NTproBNP	 and	 apelin	 at	 each	 visit	 are	 detailed	 in	 table	 17.	 There	 were	 no	




















































	 1	Hour	 1	Month	 3	Months	 6	Months	
NTproBNP	 Apelin	 NTproBNP	 Apelin	 NTproBNP	 Apelin	 NTproBNP	 Apelin	
CVi	 18.47	 6.84	 36.75	 9.23	 40.98	 9.49	 46.02	 10.19	
CVg	 28	 14	 28	 16	 32	 15	 32	 16	
II	 0.65	 0.48	 1.31	 0.58	 1.28	 0.63	 1.44	 0.64	
RCV	
(%)	






hour	 CVi,	 significant	 variability	 was	 seen	 across	 all	 time	 points	 for	 NTproBNP;	 one	 hour	 to	 one	















	 1	Hour	 1	Month	 3	Months	 6	Months	
NTproBNP	 Apelin	 NTproBNP	 Apelin	 NTproBNP	 Apelin	 NTproBNP	 Apelin	
CVi	 18.47	 6.84	 36.15	 9.58	 41.54	 10.55	 42.92	 10.19	
CVg	 28	 14	 29	 16	 32	 14	 34	 16	
II	 0.65	 0.48	 1.25	 0.61	 1.28	 0.74	 1.39	 0.66	
RCV		
(%)	




Paired	 t-tests	 were	 used	 to	 examine	 differences	 in	 CVi	 across	 the	 time	 points.	 After	 removal	 of	
patients	experiencing	a	CV	admission,	variability	for	NTproBNP	remained	significant	across	all	time	
points;	one	hour	 to	one	month	p=0.029,	one	hour	 to	 three	months	p=0.019	and	one	hour	 to	 six	










































p=0.020	 and	 AUC	 0.714;	 95%	 CI	 0.540	 to	 0.889;	 p=0.075	 vs.	 AUC	 0.641;	 95%	 CI	 0.470	 to	 0.813;	











and	 percentage	 changes	 from	 baseline	 to	 follow-up	 measurement.	 Median	 (Interquartile	 Range	
(IQR))	percentage	changes	for	the	group	overall	and	for	those	with	and	without	a	CV	admission	are	
shown	 in	 table	 21.	 Although	 differences	 were	 observed	 at	 each	 time	 point	 for	 both	 apelin	 and	
NTproBNP	 between	 those	 experiencing	 a	 CV	 admission	 and	 those	 who	 did	 not,	 no	 statistical	
significance	was	demonstrated.	
	



























Baseline	 	 50	 -	 -	 -	 -	 -	 -	
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ROC	 analysis	 of	 absolute	 changes	 showed	 apelin	was	 no	 better	 than	NTproBNP	 at	 predicting	 CV	
admission	at	one	month	(AUC	0.508;	95%	CI	0.172	to	0.843;	p=0.965	vs.	AUC	0.538;	95%	CI	0.133	to	
0.943;	 p=0.828)	 (figure	 34),	 three	months	 (AUC	 0.483;	 95%	 CI	 0.273	 to	 0.694;	 p=0.896	 vs.	 AUC	











































Insufficient	 events	 occurred	 at	 one	month	 to	 allow	meaningful	 analysis	 at	 this	 time	 point.	 ROC	
analysis	showed	no	significant	relationship	between	absolute	or	percentage	change	concentrations	
of	apelin	and	worsening	renal	function	(³25%	increase	in	creatinine)	at	either	three	months	(AUC	
0.791;	 95%	 CI	 0.639	 to	 0.942;	 p=0.095	 and	 AUC	 0.209;	 95%	 CI	 0.070	 to	 0.349;	 p=0.095)	 or	 six	







and	six	months.	Clearly	whilst	this	could	have	 implications	for	serial	monitoring,	 it	 is	unlikely	that	
any	monitoring	policy	would	 include	 sampling	at	 time	points	 as	 short	 as	one	hour.	Although	not	
assessed	in	this	study,	it	would	be	necessary	to	evaluate	BV	and	RCV	at	a	minimum	of	two	weeks,	
the	 current	 recommended	 follow-up	 time	post	 discharge	 following	 acute	decompensation	 in	 the	





monitoring	chronic	HF.	 Furthermore,	 the	high	 index	of	 individuality	of	>0.6	at	 time	scales	of	one	








Several	 studies	 have	 reported	 on	 observed	 changes	 in	 apelin	 levels	 following	 various	 treatment	
modalities.	In	a	study	of	eleven	patients	with	advanced	HF	undergoing	left	ventricular	assist	device	
implantation,	 Chen	 et	 al	 demonstrated	 that	 expression	 of	 the	 APJ	 receptor	 was	 significantly	
reduced.	 In	 the	 same	 cohort,	 repeated	 sampling	 at	 the	 time	 of	 transplantation	 revealed	




normal	 apelin	 concentrations	 nine	months	 post	 device	 implantation	 in	 those	 deemed	 to	 be	 CRT	
‘responders’(248).	These	changes	represented	a	doubling	of	apelin,	but	were	also	documented	in	the	




Although	 a	 decrease	 in	 apelin	 concentration	 was	 observed	 in	 those	 patients	 experiencing	 a	 CV	
admission	at	one	month,	this	failed	to	reach	significance.	The	trend	was	also	not	observed	over	the	
three	 or	 six-month	 follow-up,	 making	 any	 conclusive	 interpretation	 of	 this	 result	 impossible.	
Overall,	 neither	 absolute	 nor	 percentage	 changes	 in	 apelin	 showed	 any	 ability	 to	 predict	 CV	
admission	in	stable	chronic	HF	patients.		
	
No	 studies	 to	 date	 have	 examined	 the	 effect	 of	 initiation	 and	 optimisation	 of	 evidence	 based	








those	 patients	 undergoing	 optimisation	 –	where	 it	 would	 be	 expected	 to	 see	 a	 rise	 in	 apelin	 as	
therapy	is	introduced	and	up	titrated.	Given	that	this	study	required	all	patients	to	be	on	optimum	
doses	 of	 prognostic	 medication,	 it	 is	 unknown	 how	 apelin	 concentrations	 behave	 under	 these	
circumstances.	 Moreover,	 despite	 optimisation,	 median	 concentrations	 in	 this	 cohort	 remained	
below	that	of	the	normal	reference	range,	despite	relatively	low	levels	of	NTproBNP.			
	






The	biological	 variability	of	apelin	 is	 significantly	 lower	 than	 that	of	NTproBNP,	but	 this	does	not	

























Soluble	 ST2	 (sST2)	 is	 a	member	of	 the	 interleukin	1	 (IL-1)	 receptor	 family	 that	has	 recently	been	
identified	as	a	novel	biomarker	for	cardiac	remodelling	and	fibrosis.	Several	studies	have	shown	it	
to	be	a	 strong	prognostic	marker	 in	 acute/recently	decompensated	HF(138,	 258-261).	 Compared	with	
the	 B-type	 natriuretic	 peptides,	 its	 release	 is	 less	 affected	 by	 obesity,	 age,	 atrial	 fibrillation,	
aetiology,	or	prior	diagnosis	of	HF	-	making	it	an	attractive	candidate	for	monitoring.	To	date,	three	
studies	have	provided	evidence	for	the	prognostic	role	of	serial	measures	of	sST2	in	patients	with	























The	 distributions	 of	 all	 results	 for	 NTproBNP	 and	 sST2	 were	 non-parametric.	 Concentrations	 of	
NTproBNP	and	sST2	at	each	visit	are	detailed	in	table	22.	There	were	no	significant	differences	in	
median	 concentrations	 from	 baseline	 across	 the	 time	 points	 for	 either	 NTproBNP	 (one	 hour	















































	 1	Hour	 1	Month	 3	Months	 6	Months	
NTproBNP	 sST2	 NTproBNP	 sST2	 NTproBNP	 sST2	 NTproBNP	 sST2	
CVi	 18.47	 9.99	 36.75	 12.02	 40.98	 12.23	 46.02	 16.41	
CVg	 28	 33	 28	 29	 32	 25	 32	 30	
II	 0.65	 0.30	 1.31	 0.41	 1.28	 0.48	 1.44	 0.54	
RCV	
(%)	





hour	 CVi,	 significant	 variability	 was	 seen	 across	 all	 time	 points	 for	 NTproBNP;	 one	 hour	 to	 one	
month	 p=0.003,	 one	 hour	 to	 three	 months	 p<0.001,	 and	 one	 hour	 to	 six	 months	 p=0.003.	
Variability	 for	 sST2	 existed	 only	 between	 one	 hour	 and	 six	 months;	 one	 hour	 to	 one	 month	
p=0.362,	one	hour	to	three	months	p=0.382,	and	one	hour	to	six	months	p=0.019.	
	












	 1	Hour	 1	Month	 3	Months	 6	Months	
NTproBNP	 sST2	 NTproBNP	 sST2	 NTproBNP	 sST2	 NTproBNP	 			sST2	
CVi	 18.47	 9.99	 36.15	 12.44	 41.54	 12.98	 				42.92	 13.54	
CVg	 28	 33	 29	 30	 32	 36	 							34	 			32	
II	 0.65	 0.30	 1.25	 0.41	 1.28	 0.36	 					1.39	 		0.43	
RCV	
(%)	




Paired	 t-tests	 were	 used	 to	 examine	 differences	 in	 CVi	 across	 the	 time	 points.	 After	 removal	 of	
patients	experiencing	a	CV	admission,	variability	for	NTproBNP	remained	significant	across	all	time	
points;	one	hour	 to	one	month	p=0.029,	one	hour	 to	 three	months	p=0.019	and	one	hour	 to	 six	
months	p=0.022.	For	 sST2,	however,	no	variability	was	now	observed	across	any	 time	point;	one	
hour	 to	 one	 month	 p=0.514,	 one	 hour	 to	 three	 months	 p=0.674	 and	 one	 hour	 to	 six	 months	
p=0.238.	
	










Pearson	 correlation	was	 carried	out	 to	 evaluate	 the	 relationship	 of	 baseline	NTproBNP	and	 sST2	
with	several	patient	characteristics	related	to	prognosis	(table	25).	
	
In	 keeping	 with	 previous	 studies	 on	 NTproBNP,	 baseline	 concentrations	 significantly	 correlated	
with	 LVEF	 (p=0.001),	 end	 diastolic	 volume	 (EDV)	 (p=0.011),	 duration	 of	QRS	 complex	 on	 12	 lead	
ECG	(p=0.008),	NYHA	class	(p=0.042),	creatinine	(p=0.006)	and	eGFR	(p=0.012).		
	























NTproBNP	 to	 be	 better	 than	 sST2	 at	 predicting	 CV	 admission	 over	 the	 six	 month	 study	 period	
(figures	40	and	41)	(AUC	0.764;	95%	CI	0.619	to	0.910;	p=0.028,	AUC	0.780;	95%	CI	0.636	to	0.924;	
p=0.020	 and	 AUC	 0.714;	 95%	 CI	 0.540	 to	 0.889;	 p=0.075	 vs.	 AUC	 0.582;	 95%	 CI	 0.334	 to	 0.831;	
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ROC	 analysis	 of	 absolute	 changes	 showed	 sST2	 was	 no	 better	 than	 NTproBNP	 at	 predicting	 CV	
admission	at	one	month	(AUC	0.455;	95%	CI	0.074	to	0.835;	p=0.794	vs.	AUC	0.538;	0.133	to	0.943;	
p=0.828)	 (figure	44)	or	 three	months	 (AUC	0.379;	95%	CI	0.118	 to	0.640;	p=0.133	vs.	AUC	0.296;	
95%	CI	0.046	to	0.546;	p=0.110)	(figure	45).	The	AUC	for	absolute	change	in	sST2	between	baseline	
















Similar	 results	were	observed	 for	percentage	 changes	 in	 sST2	and	NTproBNP,	with	no	 significant	
ability	to	predict	CV	admission	at	one	month	(AUC	0.455;	95%	CI	0.074	to	0.835;	p=0.794	vs.	AUC	
0.455;	95%	CI	0.142	 to	0.767;	p=0.794)	 (figure	47)	or	 three	months	 (AUC	0.404;	95%	CI	0.138	 to	
0.671;	p=0.453	vs.	AUC	0.325;	95%	CI	0.100	to	0.550;	p=0.171)	(figure	48).	The	AUC	for	percentage	
change	 in	sST2	between	baseline	and	six	months	was	0.734	 (95%	CI	0.51	to	0.95;	p=0.05).	As	 for	

















or	 three	 months	 (baseline	 p=0.581,	 one	 month	 p=0.385,	 three	 months	 p=0.719).	 Significant	
correlation	 was,	 however,	 observed	 at	 six	 months	 (p=0.009).	 No	 correlation	 with	 eGFR	 was	
























Compared	 with	 NTproBNP,	 sST2	 had	 significantly	 lower	 biological	 variability	 at	 all	 time	 points	




not	 assessed	 in	 this	 study,	 as	 with	 apelin,	 it	 would	 be	 necessary	 to	 evaluate	 BV	 and	 RCV	 at	 a	
minimum	of	two	weeks,	the	current	recommended	follow-up	time	post	discharge	following	acute	








Further	 support	 for	 these	 findings	 is	 the	 low	 Index	 of	 Individuality	 of	 sST2,	 indicating	 significant	
differences	 between	 individuals	 relative	 to	 the	 population.	 Consequently,	 single	 concentrations	
cannot	 be	 effectively	 compared	 to	 a	 population-based	 reference	 range	 -	 with	 serial	 sampling	
providing	more	meaningful	 comparisons.	 In	 the	 case	of	 sST2,	 the	 calculated	 index	 is	 higher	 than	
that	 previously	 reported	 in	 healthy	 individuals(266).	 This	 appears	 to	 be	 the	 results	 of	 lower	
calculated	 CVg	 –	 and	 therefore	 lower	 variation	 between	 individuals.	 The	 reason	 for	 this	 lower	
variability	 within	 the	 chronic	 HF	 population	 compared	 to	 controls	 is	 somewhat	 surprising	 and	
should	be	validated	in	further	studies.	Despite	these	higher	values,	however,	overall	the	calculated	






Despite	 these	 promising	 biological	 variability	 results,	 serial	 and	 absolute	 changes	 in	 sST2	 in	 the	
same	 cohort	 were	 statistically	 no	 better	 than	 NTproBNP	 at	 predicting	 CV	 admission	 over	 a	 six-
month	 period.	 Results	 at	 six-months,	 however,	 almost	 reached	 statistical	 significance	 on	 ROC	
analysis.	Moreover,	analysis	of	median	percentage	sST2	changes	at	six	months	did	demonstrate	a	




of	 the	 Prospective	 Randomized	 Amlodipine	 Survival	 Evaluation	 2	 (PRAISE-2)	 trial	 demonstrated	
that,	 in	 161	 patients	with	 NYHA	 class	 III-IV	 non-ischaemic	 HF,	 changes	 in	 sST2	 over	 a	 two-week	
period	were	associated	with	an	increased	risk	of	death	or	transplantation(257).		
	
As	 in	 this	 study,	however,	no	 such	association	was	observed	with	 single	baseline	measurements.	
One	possible	explanation	for	such	findings	may	relate	to	the	shorter	time	intervals	and	chronicity	of	
symptoms	examined.	Whilst	sST2	is	linked	with	myocardial	hypertrophy	and	fibrosis,	both	of	these	
are	 late	manifestations	 of	 cardiac	 disease,	 occurring	over	 several	months.	 By	 examining	patients	
with	stable	chronic	disease,	it	could	be	argued	that	the	baseline	concentrations	of	sST2	measured	
reflect	 ‘background	 levels’	 for	 these	 individuals,	 which	 would	 then	 be	 expected	 to	 rise	 in	
accordance	with	 acute	 decompensation	 –	 resulting	 in	 a	 change	 in	 serial	measurements.	 Indeed,	
results	from	my	own	study	support	this	hypothesis,	showing	that	median	baseline	sST2	levels	were	
in	 fact	within	 the	 reference	 range	 for	 the	 assay	 utilised	 in	 this	 study.	Moreover,	 given	 that	QRS	
width	is	associated	with	degree	of	fibrosis(322),	this	may	also	go	some	way	to	explain	the	correlation	
with	baseline	sST2	observed	in	this	study;	identifying	those	with	higher	‘background	levels’	of	sST2	
and	 possibly	 higher	 degrees	 of	 underlying	 fibrosis.	 Whilst	 such	 individuals	 may	 indeed	 be	 at	
increased	 long-term	 risk,	 a	 follow-up	of	only	 six-months	 in	 this	 study	may	be	 insufficient	 to	 fully	





would	be	difficult	 to	detect	 in	 the	small	numbers	 recruited.	Future	studies	could	 incorporate	 the	
use	of	cardiac	magnetic	resonance	 imaging	to	 further	classify	 the	degree	of	 fibrosis	 in	the	cohort	
under	examination	and	how	this	relates	to	sST2	levels.		
	
It	 should	 be	 remembered,	 however,	 that	 sST2	 is	 not	 merely	 a	 marker	 of	 fibrosis	 but	 is	 also	
associated	with	 immune	modulation	 and	 inflammatory	 responses(250,	 252,	 323).	 In	 the	 shorter-term,	
changes	 in	 sST2	may	 therefore	 reflect	different	underlying	processes	such	as	 inflammation	or,	as	










The	 biological	 variability	 of	 sST2	 is	 significantly	 lower	 than	 that	 of	 NTproBNP,	 but	 this	 may	 not	



























137,	 282).	Results	of	 these	studies	 indicate	 that	 increases	 in	galectin-3	concentrations	over	 time	are	
independent	 predictors	 of	 both	 mortality	 and	 HF	 hospitalisation	 in	 patients	 either	 recently	
hospitalised	 with	 decompensation	 or	 with	 known	 CAD	 and	 stable	 angina.	 The	 use	 of	 serial	
measurements	 in	 routine	 clinical	 practice,	 however,	 has	 yet	 to	be	 validated	 and	no	 studies	have	









































































CVg,	 CVi,	 index	 of	 individuality	 and	 corresponding	 reference	 change	 values	 for	 NTproBNP	 and	
galectin-3	at	each	time	point	are	shown	in	table	28.		
	 1	Hour	 1	Month	 3	Months	 6	Months	
NTproBNP	 Gal-3	 NTproBNP	 Gal-3	 NTproBNP	 Gal-3	 NTproBNP	 Gal-3	
CVi	 18.47	 12.73	 36.75	 13.98	 40.98	 14.48	 46.02	 18.13	
CVg	 28	 20	 28	 20	 32	 18	 32	 20	
II	 0.65	 0.63	 1.31	 0.69	 1.28	 0.80	 1.44	 0.90	
RCV	
(%)	





hour	 CVi,	 significant	 variability	 was	 seen	 across	 all	 time	 points	 for	 NTproBNP;	 one	 hour	 to	 one	
month	 p=0.003,	 one	 hour	 to	 three	 months	 p<0.001,	 and	 one	 hour	 to	 six	 months	 p=0.003.	










8.4.3	 Individual	 Coefficients	 of	 Variation,	 Index	 of	 Individuality	 and	 Reference	 Change	 Values:	
Stable	Patients	
CVg,	 CVi,	 index	 of	 individuality	 and	 corresponding	 reference	 change	 values	 for	 NTproBNP	 and	
galectin-3	at	each	time	point	were	re-calculated	after	removal	of	any	patients	reaching	the	primary	
end-point	of	the	study.	Results	are	shown	in	table	29.		
	 1	Hour	 1	Month	 3	Months	 6	Months	
NTproBNP	 Gal-3	 NTproBNP	 Gal-3	 NTproBNP	 Gal-3	 NTproBNP	 		Gal-3	
CVi	 18.47	 12.73	 36.15	 12.33	 41.54	 12.47	 42.92	 13.26	
CVg	 28	 20	 29	 21	 32	 20	 34	 				20	
II	 0.65	 0.63	 1.25	 0.58	 1.28	 0.62	 1.39	 		0.66	
RCV	
(%)	




Paired	 t-tests	 were	 used	 to	 examine	 differences	 in	 CVi	 across	 the	 time	 points.	 After	 removal	 of	
patients	experiencing	a	CV	admission,	variability	for	NTproBNP	remained	significant	across	all	time	






(p=0.095).	 Significant	 differences	 were,	 however,	 observed	 between	 CVi	 for	 NTproBNP	 and	









Pearson	 correlation	 was	 carried	 out	 to	 evaluate	 the	 relationship	 of	 baseline	 NTproBNP	 and	
galectin-3	 with	 several	 patient	 characteristics	 related	 to	 prognosis	 (table	 30).	 In	 keeping	 with	
previous	 studies	 on	 NTproBNP,	 baseline	 concentrations	 significantly	 correlated	 with	 LVEF	
(p=0.001),	 end	 diastolic	 volume	 (EDV)	 (p=0.011),	 duration	 of	 QRS	 complex	 on	 12	 lead	 ECG	
(p=0.008),	 NYHA	 class	 (p=0.042),	 creatinine	 (p=0.006)	 and	 eGFR	 (p=0.012).	 Although	 baseline	
























p=0.020	 and	 AUC	 0.714;	 95%	 CI	 0.540	 to	 0.889;	 p=0.075	 vs.	 AUC	 0.408;	 95%	 CI	 0.169	 to	 0.647;	









The	 value	 of	 relative	 changes	 in	 both	 NTproBNP	 and	 galectin-3	 were	 assessed	 by	 considering	
absolute	and	percentage	changes	from	baseline	to	follow-up	measurement.		
	
Median	 (Interquartile	 Range	 (IQR))	 percentage	 changes	 for	 the	 group	 overall	 and	 for	 those	with	
and	without	a	CV	admission	are	shown	in	table	31.	Differences	were	observed,	at	each	time	point,	
for	 both	 galectin-3	 and	 NTproBNP.	 Statistical	 significance,	 however,	 was	 only	 demonstrated	 for	
galectin-3	at	 six	months.	Box-plot	analysis	of	 these	 findings	 show	a	 clear	 separation	 in	galectin-3	



























Baseline	 	 50	 -	 -	 -	 -	 -	 -	
	 	 -	 	 -	 	 -	 -	

























































ROC	analysis	 of	 absolute	 changes	 showed	galectin-3	was	better	 than	NTproBNP	at	 predicting	CV	
admission	at	one	month	(AUC	0.598;	95%	CI	0.396	to	0.801;	p=0.572	vs.	AUC	0.538;	95%	CI	0.133	to	
0.943;	p=0.828)	(figure	56),	and	three	months	(AUC	0.567;	95%	CI	0.305	to	0.828;	p=0.602	vs.	AUC	

















Similar	 results	were	demonstrated	 for	percentage	change	 in	galectin-3.	At	both	one	month	 (AUC	
0.614;	95%	CI	0.386	to	0.841;	p=0.514	vs.	AUC	0.455;	95%	CI	0.142	to	0.767;	p=0.794)	(figure	59),	
and	 three	months	 (AUC	 0.563;	 95%	 CI	 0.305	 to	 0.820;	 p=0.625	 vs.	 AUC	 0.325;	 95%	 CI	 0.100	 to	
0.550;	p=0.171)	(figure	60),	galectin-3	was	better	than	NTproBNP	at	predicting	CV	admission.		Once	



































any	 other	 time	 points.	 Clearly	 this	 could	 have	 implications	 for	 serial	 monitoring,	 however	 it	 is	
unlikely	that	any	monitoring	policy	would	include	sampling	at	time	points	as	short	as	one	hour.	As	
with	 both	 apelin	 and	 sST2,	 it	would	 be	necessary	 to	 evaluate	BV	 and	RCV	 at	 a	minimum	of	 two	
weeks,	the	current	recommended	follow-up	time	post	discharge	following	acute	decompensation	
in	the	UK(302),	in	order	to	establish	reliable	BV	components.	Moreover,	after	removal	of	the	results	
of	 patients	 who	 experienced	 a	 CV	 admission,	 this	 significant	 difference	 was	 no	 longer	














two	 month	 II	 of	 galectin-3	 of	 1.00	 and	 1.01	 respectively.	 	 Despite	 this,	 however,	 my	 results	
demonstrate	 that	 both	 absolute	 and	 percentage	 changes	 in	 galectin-3	 were	 significantly	 better	







in	 galectin-3	 over	 six	 months	 did	 not	 add	 prognostic	 information	 to	 the	 baseline	 concentration	
alone(278),	more	recent	studies	have	disputed	this	finding(136).	This	study	provides	added	evidence	to	
the	 argument	 that	 such	 changes	 are	 indeed	 related	with	 prognosis.	 Specifically,	 it	 demonstrates	
that,	 even	 in	 a	 stable,	 fully	 optimised	 cohort,	 not	 only	 do	 galectin-3	 concentrations	 change	over	
time,	but	that	at	six	months,	these	changes	are	more	closely	related	to	the	outcome	measure	of	CV	
admission	 than	 paired	 changes	 in	 the	 natriuretic	 peptide	 NTproBNP.	 Furthermore,	 this	 study	








optimal	 for	 providing	 additional	 prognostic	 information	 than	 measurements	 at	 any	 earlier	 time	
point.	In	contrast	to	these	previous	studies,	however,	I	was	unable	to	demonstrate	any	significant	
relationship	between	galectin-3	changes	of	>15%	and	CV	admission.	
Galectin-3	 concentrations	 have	 previously	 been	 shown	 to	 correlate	 with	 renal	 function.	 In	 this	
study	 I	 demonstrate	 that,	 although	 single	 absolute	 concentrations	 at	 each	 time	 point	 correlated	
with	 both	 creatinine	 and	 eGFR,	 no	 such	 correlation	 existed	 for	 either	 absolute	 or	 percentage	
change.	Moreover,	serial	measurements	were	not	shown	to	predict	worsening	renal	function	over	
the	six-month	study	period.	Such	 findings	 indicate	 that	changes	 in	galectin-3	are	not	 significantly	
related	to	changes	in	renal	function,	either	as	a	result	of	decompensated	heart	failure	per	se,	or	as	






The	 biological	 variability	 of	 galectin-3	 is	 significantly	 lower	 than	 that	 of	 NTproBNP.	 Moreover,	
percentage	and	absolute	changes	in	galectin-3	are	better	predictors	of	CV	admission	than	those	of	
NTproBNP	 in	 patients	 with	 stable	 chronic	 HF.	 These	 findings	 suggest	 that,	 compared	 with	
NTproBNP,	 galectin-3	may	be	a	better	biomarker	 for	monitoring	patients	with	 stable	 chronic	HF.	
The	use	of	serial	measurements	may	allow	safer	discharge	of	patients	for	monitoring	by	community	
teams/general	 practitioners.	 Questions	 remain,	 however,	 as	 to	 how	 prognostic	 therapies	 effect	
galectin-3	 levels.	 Further	 larger	 prospective	 randomised	 controlled	 trials	 examining	 the	 use	 of	
















Multi-markers	strategies	are	 increasingly	used	as	clinical	 tools	 in	 the	risk	stratification	of	patients	














that	 simultaneous	 assessment	 of	 pathophysiologically	 diverse	 biomarkers	 would	 provide	
complementary	prognostic	 information,	 irrespective	of	the	eventual	causal	diagnosis.	 In	this,	they	
examined	 several	 of	 the	 novel	 biomarkers	 presented	 in	 this	 thesis,	 including	 sST2,	 galetin-3	 and	
apelin,	as	well	as	NTproBNP.	Using	data	from	the	PRIDE	study(169),	ROC	analysis	was	used	to	identify	
candidate	markers	for	prediction	of	mortality	at	one	year	–	with	a	minimum	AUC	of	0.7	selected	as	
the	 cut	 off	 for	 inclusion	 in	 the	multi-marker	model.	 In	 addition,	 those	 identified	were	 tested	 for	
statistical	 significance	 for	 independent	 prognostic	 ability	 and	 only	 if	 both	 conditions	 were	 met,	
were	 the	 markers	 included	 in	 the	 final	 model.	 Using	 this	 strategy,	 neither	 galectin-3	 or	 apelin	
demonstrated	sufficient	significance	and	were	therefore	excluded,	with	the	final	model	consisting	











peptides(332,	 333).	 Of	 the	 novel	 biomarkers	 in	 this	 present	 study,	 promising	 results	 have	 been	
demonstrated	for	the	addition	of	all	except	apelin.	In	a	study	of	599	patients	with	acute	dyspnoea,	
the	combination	of	galectin-3	to	NTproBNP	was	the	best	predictor	of	60-day	mortality	in	subjects	
with	acute	HF	 (243).	 In	the	same	study,	apelin	was	not	 found	to	be	of	any	diagnostic	or	prognostic	
benefit.	In	a	much	larger,	international	trial	of	over	5,000	patients,	Lassus	et	al	demonstrated	that	
the	 addition	 of	 NT-proBNP,	 CRP,	 MR-proADM	 and	 sST2	 to	 the	 clinical	 model,	 resulted	 in	
significantly	higher	c-statistics	for	the	prediction	of	30-day	mortality(261).	
	






















Of	 the	 novel	 biomarkers,	 apelin	 was	 shown	 to	 correlate	 with	 MRproADM	 (p=0.008).	 No	 other	
correlation	was	demonstrated.	
	 NTproBNP	 MRproADM	 Apelin	 sST2	 Galectin-3	
NTproBNP	 1.00	 0.486**	 0.244	 0.033	 0.289*	
MRproADM	 0.486**	 1.00	 0.373**	 0.129	 0.044	
Apelin	 0.244	 0.373**	 1.00	 0.094	 0.018	
sST2	 0.033	 0.129	 0.094	 1.00	 -0.077	



























Despite	 attempts	 to	 perform	 a	 Cox	 proportional	 hazards	 analysis,	 unfortunately	 too	 few	 events	
occurred	to	allow	any	meaningful	statistical	analysis	to	take	place.	With	only	eight	events	over	the	














available	 for	 only	 seven,	 further	 degrading	 any	 statistical	 power.	 Examining	 these	 patients	 with	
respect	 to	percentage	changes	 in	biomarker	concentrations	compared	 to	 the	median	percentage	
change	over	 six-months	does	 reveal	a	 trend	 towards	 sST2	and	galectin-3	being	potentially	useful	
(table	 33).	 Of	 the	 four	 novel	 biomarkers,	 percentage	 changes	 in	 these	 two	markers	were	 raised	
above	the	median	 in	six	of	 the	seven	patients	 (86%).	This	compared	with	NTproBNP,	MRproADM	
and	apelin	all	of	which	demonstrated	almost	equal	numbers	of	patients	with	changes	above	and	
below	the	median	change	for	the	entire	cohort.		
Patient	 NTproBNP	 MRproADM	 Apelin	 sST2	 Galectin-3	
1	 ê	 é	 ê	 é	 é	
2	 Six-month	sample	lost	after	arrival	in	lab	
3	 ê	 ê	 ê	 é	 é	
4	 é	 é	 ê	 é	 é	
5	 ê	 ê	 é	 é	 é	
6	 ê	 ê	 ê	 ê	 é	
7	 é	 é	 é	 é	 é	
















Moreover,	 it	 should	 be	 noted	 that,	 in	 order	 to	 allow	 any	 type	 of	 analysis,	 results	 were	 pooled	
across	 the	 study	 period	 of	 six	months,	 rather	 than	 being	 analysed	 in	 relation	 to	 admission	 time	
point.	 Details	 of	 admission	 relative	 to	 recruitment	 have	 been	 described	 previously	 and	 can	 be	
found	in	section	4.1,	table	10.	Interestingly,	it	should	be	noted	that	those	with	the	highest	number	







Patient	 NTproBNP	 MRproADM	 Apelin	 sST2	 Galectin-3	 Time	from	recruitment	
to	admission	(days)	
1	 ê	 é	 ê	 é	  é	 41	
2	 Six-month	sample	lost	after	arrival	in	lab	 147	
3	 ê	 ê	 ê	 é	  é	 23	
4	 é	 é	 ê	 é	  é	 68	
5	 ê	 ê	 é	 é	  é	 26	
6	 ê	 ê	 ê	 ê	  é	 13	
7	 é	 é	 é	 é	  é	 156	










the	 small	 sample	 size,	 follow-up	period	and	subsequent	event	 rate	 resulted	 in	 too	 few	results	 to	





































the	 small	 sample	 size	 represents	 the	 most	 significant	 limitation	 of	 the	 study.	 As	 a	 result,	 it	 is	
underpowered	with	respect	to	the	number	of	events	and	therefore	to	detect	statistical	significance	
at	 time	 points	 earlier	 than	 at	 the	 six	 months	 demonstrated,	 or	 conduct	 multivariate	 or	 hazard	
analyses.	In	contrast	to	previous	studies,	I	was	unable	to	demonstrate	correlation	with	prognosis	by	
baseline	concentrations	or	any	specific	thresholds	of	change.	Again,	this	is	likely	due	to	the	sample	





This	 study,	 however,	 was	 designed	 as	 a	 pilot	 study	 to	 stimulate	 interest	 in	 the	 most	 promising	
biomarkers.	In	this	sense,	this	body	of	work	has	achieved	its	aim.	Moreover,	the	sample	size	reflects	
the	 stringent	 nature	 of	 the	 entry	 criteria	 to	 ensure	 recruitment	 was	 restricted	 to	 those	 truly	
pharmacologically	 optimised	 and	 stable	 at	 baseline.	 This	 fact	 is	 further	 corroborated	 by	 the	
relatively	 low	 median	 biomarker	 concentrations	 observed	 at	 baseline	 and	 subsequently	 at	 each	















In	 order	 to	 improve	 the	 assessment	 of	 functional	 capacity,	 future	work	 could	 incorporate	more	
objective	measures	 such	 as	 a	 six-minute	walk	 test.	 Previous	 studies	 have	demonstrated	 that	 six-
minute	walk	 distance	 is	 an	 independent	 predictor	 of	 hospital	 admission	 in	 patients	with	 chronic	





As	 previously	 discussed,	 one	 of	 the	 main	 limitations	 of	 this	 study	 relates	 to	 the	 sample	 size	
recruited.	In	addition	to	the	innate	difficulties	in	statistical	power	a	small	sample	size	portends,	the	






acknowledged	 that	 mortality	 should	 have	 been	 accounted	 for	 and	 that	 an	 endpoint	 of	 CV	










Although	 a	 six-month	 study	 period	 was	 sufficient	 for	 analysis	 of	 biological	 variability	 across	 the	
biomarkers	of	interest,	 it	 is	acknowledged	that	the	short	follow-up	period	negatively	impacted	on	
the	 serial	monitoring	 aspect	 of	 the	 study.	Whilst	 patients	with	 end-stage	 HF	 are	 highly	 likely	 to	
experience	a	CV	related	admission	over	a	six-month	period,	this	 is	 less	 likely	 in	those	with	milder	
symptoms.	 Given	 the	 population	 of	 interest,	 the	 monitoring	 aspect	 of	 this	 study	 would	 have	
benefitted	 from	 a	 significantly	 longer	 follow-up	 period,	 with	 the	 ability	 to	 identify	 outcomes	 of	




Only	 single	 samples	were	 collected	 at	 each	 time	point.	 Clinical	 chemistry	 practice	 has	 suggested	
that	although	duplicate	samples	 result	 in	a	 reduction	of	CVa,	 this	will	 result	 in	double	 the	cost	of	
reagents	and	is	only	useful	if	the	CVa	is	>50%	of	the	CVi.	Under	these	conditions,	it	is	estimated	that	
the	assay	imprecision	will	add	only	10%	to	the	biological	variability(266).	Results	of	percentage	CVa	of	
CVi	 for	 each	 of	 the	 biomarkers	 in	 this	 study	 for	 all	 patients	 and	 for	 those	 not	 experiencing	 a	 CV	
admission	are	shown	in	tables	34	and	35.	
	 Percentage	CVa	of	CVi	
One	hour	 One	Month	 Three	Months	 Six	Months	
NTproBNP	 23	 11	 10	 9	
MRproADM	 35	 37	 35	 25	
Apelin	 52	 38	 37	 35	
sST2	 48	 40	 39	 29	







One	hour	 One	Month	 Three	Months	 Six	Months	
NTproBNP	 23	 12	 10	 10	
MRproADM	 35	 39	 39	 41	
Apelin	 52	 37	 34	 35	
sST2	 48	 39	 37	 36	




It	 could	 be	 argued,	 therefore,	 that	 with	 a	 CVa	 of	 >50%	 the	 CVi	 of	 apelin	 at	 one	 hour,	 assay	








the	majority	 of	 assays	 for	 a	 particular	 marker	 employ	 the	 same	 technique,	 assays	 may	 exist	 to	
differing	parts	of	the	peptide	and	indeed	to	different	isoforms.	Moreover,	different	companies	will	
each	develop	its	own	assay	with	inherent	differences	to	that	produced	by	other	companies.	From	











based	assays	have	become	commercially	available	 for	 the	 research	market.	The	majority	of	 large	
trials	assessing	the	use	of	MRproADM	in	HF	populations	have,	however,	used	the	original	KRYPTOR	




Methods	 for	 apelin	 detection	 include	 enzyme	 immunoassays	 (EIAs)	 and	 radioimmunoassays	
(RIAs)(341,	 342).	 Most	 assays	 use	 antibodies	 to	 target	 the	 conserved	 C-terminal	 domain	 in	 these	
peptides,	 effectively	 measuring	 the	 total	 amount	 of	 apelin	 present.	 To	 characterize	 the	 specific	
forms	 of	 apelin	 present,	 gel	 filtration	 or	 high-performance	 liquid	 chromatography	 separation	
approaches	coupled	with	apelin-like	 immunoreactivity	detection	have	been	used	 routinely.	Using	




to	 be	 effective	 alternative	methods	 for	 apelin	 quantification	 and	 characterization(344,	 345).	 In	 one	
study,	 the	 apelin	 concentrations	 for	 the	 same	 samples	 measured	 using	 a	 modified	 MS-based	
method	and	a	widely-used	EIA	method	were	compared.	The	apelin	concentrations	measured	using	
EIA	 were	 demonstrated	 to	 be	 much	 higher	 than	 the	 concentrations	 determined	 by	 MS(346),	
corroborating	 previous	 observations	 reported	 by	 Mesmin	 and	 coworkers(344).	 These	 disparate	
results	 require	 additional	 studies	 to	 understand	 this	 discrepancy	 in	 detail.	 It	 has	 been	 proposed	
that	higher	concentrations	detected	by	EIA	may	be	a	result	of	measuring	apelin	immunoreactivity,	





isoforms	may	 not	 be	 readily	 detected	 by	 the	MS-based	methods,	 which	 are	 thought	 to	 reliably	
detect	only	the	known	biologically	active	forms	of	apelin.	No	studies	have	looked	at	the	impact	of	






assay,	 studies	 looking	 at	 sST2	 in	 chronic	 HF	 have	 used	 a	 variety	 of	 all	 three.	 Mueller	 et	 al(347)	
performed	 a	 comparison	 of	 plasma	 concentrations	 by	 the	 three	 assays	 and	 found	 considerable	
differences	 between	 concentrations	 obtained.	 Results	 between	 the	methods	 are,	 therefore,	 not	




assay	utilised.	 To	date,	 there	are	no	 comparative	 studies	assessing	 the	BV	of	 sST2	 in	 chronic	HF.	








Similarly,	 there	 are	 five	 commercially	 available	 assays	 to	 galectin-3.	Most	 studies	 have	 used	 the	







study.	As	with	sST2,	 there	 is	no	evidence	to	suggest	superiority	of	any	one	assay	over	 the	others	
and	CVi	 should	 be	 consistent	 regardless	 of	 the	 assay	 utilised.	 To	date,	 there	 are	 no	 comparative	
studies	assessing	the	BV	of	galectin-3	 in	chronic	HF.	Wu	et	al(266)	recently	examined	the	biological	




















Heart	 failure	 is	 a	 serious	 health	 condition,	 imparting	 significant	 morbidity	 and	 mortality	 to	 its	
sufferers.	 Worldwide	 17–45%	 of	 patients	 admitted	 to	 hospital	 with	 HF	 die	 within	 1	 year	 of	
admission	 and	 the	 majority	 die	 within	 5	 years	 of	 admission(17). In	 terms	 of	 total	 healthcare	
expenditure,	 it	 accounts	 for	 about	 1–3%	of	 that	 in	most	 developed	 countries,	 including	 those	of	
North	America(348),	Western	Europe(349)	and	Latin	America(350).	The	majority	of	this	burden	comes	as	
a	result	of	the	often	 lengthy	and	repeated	hospital	stays	that	are	typically	required(349,	 351).	Whilst	
such	 hospital	 readmissions	 can	 improve	 survival	 rates	 among	 patients	 with	 worsening	 HF,	
outpatient	 management	 and	 avoidance	 of	 admission	 is	 undoubtedly	 preferable	 and	 a	 more	
efficient	use	of	resources(352). 
	
Risk	 stratification	 and	 identification	 of	 patients	 with	 stable	 chronic	 HF	 who	 are	 likely	 to	
decompensate	is,	however,	imprecise.	In	the	UK,	fear	of	discharging	optimised	patients	to	general	
practice	where	adherence	may	not	be	maintained	has	previously	deterred	those	in	secondary	and	
tertiary	 care	 from	 this	 option,	 with	 inevitable	 consequences	 on	 available	 hospital	 outpatient	
resources.	 Results	 from	 both	 the	 NorthStar(353)	 and	 COACH-2(354)	 trials	 have	 indicated	 that	 those	
who	 are	 pharmacologically	 optimised	 may	 indeed	 be	 safe	 to	 discharge	 to	 general	 practice.	














	pharmacologically	 optimised	 patients,	 both	 in	 terms	 of	 their	 biological	 variability	 and	 how	 this	










examined	 over	 the	 six-month	 period,	 apelin	 showed	 no	 ability	 to	 predict	 CV	 admission	 in	 this	
cohort	of	patients.		
	
Both	 MRproADM	 and	 sST2	 produced	 similar,	 overlapping	 results.	 MRproADM	 demonstrated	 a	
slightly	 higher	 degree	 of	 inter-individual	 variation,	 and	 sST2	 showed	 a	 slightly	 higher	 index	 of	
individuality,	albeit	still	within	the	range	of	acceptability	for	comparing	results	within	an	individual	
rather	 than	 to	 a	 population.	 Both	 biomarkers,	 however,	 exhibited	 low	 intra-individual	 variability	
and	reference	change	values	in	the	order	of	30-50%	over	the	six-month	study	period.	Interestingly,	
despite	these	similarities,	when	changes	in	concentration	of	MRproADM	and	sST2	were	examined	
for	 their	 ability	 to	 predict	 decompensation	 in	 the	 form	 of	 CV	 admission,	 there	 was	 a	 clear	
difference	 in	performance.	 In	 this	 respect,	 changes	 in	 sST2	 showed	substantially	better	 ability	 to	
predict	admission	compared	to	MRproADM.	This	cannot	be	solely	explained	by	the	slightly	higher	







This	 finding	 is	 further	 corroborated	 by	 the	 results	 of	 galectin-3.	 Despite	 similar	 intra-individual	
variation	and	reference	change	values	to	both	MRproADM	and	sST2,	galetin-3	exhibited	high	index	
of	 individuality.	 Indeed,	 this	 was	 in	 the	 order	 of	 that	 seen	 with	 NTproBNP	 and,	 as	 with	 apelin,	
should	result	in	poor	ability	to	reflect	changes	within	an	individual	as	compared	to	the	population.	
In	fact,	results	from	the	serial	monitoring	aspect	of	the	study	revealed	changes	in	concentrations	of	
galectin-3	 within	 an	 individual	 to	 be	 the	 overall	 best	 predictor	 of	 CV	 admission,	 demonstrating	
better	results	than	sST2	for	this	purpose.		
	
Similarly,	 differences	 in	 biomarker	 monitoring	 suitability	 were	 observed	 when	 worsening	 renal	
function	 was	 examined.	 Despite	 its	 ability	 to	 predict	 CV	 admission	 and	 significant	 baseline	
correlations	 with	 creatinine	 and	 eGFR,	 changes	 in	 galectin-3	 demonstrated	 no	 ability	 to	 predict	
changes	in	renal	function.	On	the	other	hand,	sST2,	showed	no	correlation	with	either	creatinine	or	





time	 period.	 Thus,	 although	 worsening	 renal	 function	 has	 a	 known	 prognostic	 relationship	 with	
chronic	HF,	admissions	in	this	cohort	were	not	driven	by	such	changes	-	potentially	explaining	the	




















predict	 CV	 admission	 over	 the	 study	 period.	Moreover,	 both	 galectin-3	 and	 sST2	 are	 associated	
with	 myocyte	 hypertrophy,	 with	 changes	 in	 both	 showing	 significant	 ability	 to	 predict	 CV	
admission.		
	
No	 studies,	 however,	 have	 specifically	 assessed	 the	degree	 to	which	 concentrations	of	 the	novel	
biomarkers	change	as	a	result	of	prognostically	indicated	therapy	in	the	outpatient	setting.	Clearly	
such	information	is	required	before	any	calculation	of	BV	or	RCV	can	be	used	meaningfully	in	this	
way.	 Moreover,	 there	 are	 few	 studies	 examining	 biomarker	 concentrations	 and	 variability	 in	
different	disease	states.	Indeed,	the	findings	of	an	RCV	of	MRproADM	of	112%	at	one	week	in	the	
post-operative	 OLT	 population	 by	Miguel	 et	 al(228)	 indicate	 that	 specific	 disease	 states	 may	 also	
pose	 an	 important	 variable	 on	 the	 extent	 of	 biological	 variability	 of	 any	 particular	marker.	 Such	












Future	 studies	 may	 therefore	 focus	 on	 assessing	 if	 certain	 biomarkers	 can	 be	 linked	 with	
monitoring	particular	aetiological	and	phenotypic	presentations	within	the	vast	cohort	of	patients	
labelled	with	a	chronic	HF	diagnosis.	Such	individualised	care	remains	the	ultimate	goal	of	modern	
medicine,	 but	 is	 likely	 to	 require	 approaches	 based	 on	 genetic	 factors	 as	 well	 as	 recognised	
pathophysiological	processes	and	 clinical	parameters.	 Indeed,	with	prognosis	 intricately	 linked	 to	
all	 such	 factors,	 it	 is	 likely	 that	 the	multi-marker	approach,	utilising	biomarkers	 reflecting	 several	




In	 conclusion,	 this	 thesis	 has	 provided	 the	 foundation	 for	 future	 work	 on	 selecting	 novel	
biomarkers	for	monitoring	patients	with	chronic	HF.	Results	suggest	that	more	focus	on	underling	
pathological	 processes	may	be	 key	 in	 biomarker	 selection,	with	 those	 reflecting	myocyte	 stretch	
unlikely	to	provide	long-term	success	in	this	area.	Selection	based	on	biological	variability	alone	is	
not	 recommended.	 Galectin-3	 and	 sST2	 appear	 the	 most	 promising	 of	 the	 biomarkers	 studied.	
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